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ABSTRACT 
Hengrui Sun: Controlling Multiplicity in Confirmatory Clinical Trials 
 (Under the direction of Gary G. Koch) 
 
Multiplicity is an important statistical consideration that arises in clinical trials when the efficacy 
of the test treatment is evaluated in multiple ways. The scope of multiplicity includes multiple efficacy 
endpoints, multiple inferential subgroups, multiple treatments or doses, etc. The major concern for 
multiplicity is that insufficiently controlled multiple assessments lead to an inflated family-wise (or 
experiment-wise) Type I error rate (FWER) and they thereby undermine the integrity of the statistical 
inferences. Therefore, a sound statistical strategy that controls FWER in a strong sense for the multiple 
assessments, without excessive loss of power (or Type II error) from over-control, is crucial for the 
success of the trial. 
Chapters 1 and 2 explore strategies for multiplicity issues that come from only one source, which 
may involve strictly ordinal response outcomes, stratified design, baseline imbalances, and missing 
values. Realistic case examples are provided, and solutions are proposed to address those issues 
comprehensively. 
Multiplicity can also come simultaneously from two or more sources in a confirmatory clinical 
trial. For example, a clinical trial is designed to make inferences either on the overall population or some 
pre-specified sub-populations, while multiple endpoints need to be evaluated for each population. For this 
complex multiplicity problem, we propose a strategy based on multi-way averages in Chapter 3. We 
apply this strategy to a cardiovascular clinical trial, and discuss a simulation study based on this trial to 
compare the power of the proposed strategy to some more well-known alternative approaches.  
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More than two sources of multiplicity can exist in one confirmatory clinical trial concurrently. 
Chapter 4 presents an illustrative example of a confirmatory clinical trial that is designed to have efficacy 
assessed for two or more primary endpoints, for multiple dose groups, and at two or more post baseline 
visits. The proposed strategies with multi-way averages manage the higher dose and the lower dose 
equally and enable evaluation for the multiple endpoints at multiple visits collectively. Simulation studies 
show that the proposed strategy can comprehensively meet most of the primary objectives of the trial 
effectively with reasonably high overall power. 
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CHAPTER 1 : LITERATURE REVIEW AND INTRODUCTION 
In the paradigm of statistics, testing a statistical hypothesis is one of the most important areas of 
statistical inference. A null hypothesis states that the object being studied produces no effect or makes no 
difference. Type I error occurs when a true null hypothesis is rejected. To control the type I error rate, the 
significance level of the test, α, is selected beforehand. However, an overall type I error rate can be 
inflated by analyzing the data in multiple ways, for example, for a given α at level 0.05, the overall false 
rejection rate for 5 independent tests will be 1 − (1 − 𝛼)5, which equals 0.23.  
1.1 Multiplicity Issues in Confirmatory Clinical Trials 
Multiplicity commonly arises in clinical trials when the effect of the test treatment is evaluated in 
multiple ways. For example, such multiple ways include the use of multiple efficacy endpoints when 
several aspects of disease need to be assessed; making primary inferential assessment for one or more pre-
specified subgroups; comparisons among several dose levels of a single test treatment, or more than two 
treatments. Under those situations, the trial is normally defined as a success if at least one objective is 
successful, which is sometimes known as the at-least-one-win criterion. More formally, this refers to the 
union-intersection test, which is based on the global null hypothesis that is defined as the intersection of 
the null hypotheses corresponding to the individual primary assessments: 
𝐻𝐼 = 𝐻1 ∩ 𝐻2 ∩ … ∩ 𝐻𝑚 
The global null hypothesis is rejected if at least one null hypothesis is rejected. Details of some of the 
multiplicity issues are explained in the following sections.   
1.1.1 Multiple Endpoints 
In clinical trials, there are situations where no single endpoint describes all dimensions of the effect of the 
test treatment. Thus, multiple primary response variables are present. Often, those response 
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variables are related. For example, in rheumatoid arthritis trials, there are measures of improvement that 
include physician and patient assessments (number of joints that are stiff or swollen or painful, disability 
status, global rating by physician and patient), and acute phase reactant [1]; In stroke trials, several 
measures of disability, e.g., Barthel Index, Modified Rankin Scale, Glasgow Outcome Scale, and NIH 
Stroke Scale describe the dimension of recovery for a stroke patient at 90 days [2]; in acute heart failure 
trials, the relief of the symptom, heart failure rehospitalization, time-to-worsening heart failure, and 
mortality are all important elements that should be assessed collectively for the efficacy of the test 
treatment [3].  
1.1.2 Subgroups 
It is known that different patients may respond differently to the same intervention. This 
variability in response sometimes is hard to explain but is widely recognized. The cause of the variability 
might be demographic, genomic, disease characteristics, etc. Clinical trials often enroll a relatively 
heterogeneous population so that the results can be generalizable to a reasonably larger group of patients, 
or to see whether a certain subpopulation can benefit more from the treatment.  
The role of a subgroup in clinical trials can be inferential, supportive, or exploratory based on the 
design and purpose of the trial. The inferential subgroup analysis is of primary interest in the study of 
multiplicity. In order to be evaluated in an inferential way, subgroups should be pre-specified in the 
protocol. There are basically two paradigms for this situation: a pre-specified subgroup is the only 
population for primary inference; either the primary subgroup or the overall population of all randomized 
patients is eligible for the primary inferential assessment of efficacy. An example for the latter situation 
can be seen in the clinical trial TRA 2
0
P – TIMI 50 (Thrombin Receptor Antagonist in Secondary 
Prevention of atherothrombotic ischemic event), which was conducted with 26,449 subjects stratified to 
three mutually exclusive populations, CAD (all subjects who had a history of myocardial infarction (MI), 
regardless of history of stroke or peripheral artery disease), CVD (subjects with history of ischemic 
stroke, with or without peripheral artery disease), and PAD (peripheral artery disease). The ultimate 
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objective of the trial was to evaluate treatment efficacy in the overall population, or the populations 
without CVD [4]. 
1.1.3 Multiple Treatments / Doses 
There are cases in which a confirmatory clinical trial is designed to compare multiple doses of a 
test treatment to a control group and compare doses to one another, with the interest to evaluate whether 
one or more of the doses is better than the control, and whether higher doses are better than the lower 
doses [5]. In addition, studies may need to compare a test treatment, an active control, and a placebo, or 
several single treatments and a combination treatment.   
1.1.4 Multiple Visits 
After treatments start, patients are generally followed at multiple visits over time, and treatment 
responses are recorded during each of the visits. To prove the treatment efficacy, it is ideal to pre-specify 
a visit with the analysis plan for the maximum effect size so that it can be tested with sufficient power at 
the selected visit. However, choosing the “best” visit is not an easy task. For example, a randomized 
clinical trial to compare a test treatment to placebo for a respiratory disorder that had four post baseline 
visits with corresponding ordinal response variable measured at each of the visits [6] may not have the 
“best” visit known beforehand.    
The main concern for the multiplicity problem in the Phase III confirmatory clinical trial is that 
insufficiently controlled multiple assessments lead to multiple opportunities for the findings of a clinical 
trial to be due to chance. Without appropriate control, the trial loses its validity because of the inflation of 
Type I error.  
1.2 FWER and Its Considerations in Confirmatory Clinical Trials 
The family wise (or the experiment wise) Type I error rate (FWER) is the probability of 
incorrectly finding a beneficial treatment effect for at least one objective among those that have no 
beneficial effects. A procedure controls the FWER in the weak sense if the error rate control at level α is 
guaranteed only when all null hypotheses are simultaneously true. Strong control of FWER means that 
the error rate control at level α is guaranteed for any configuration of true and non-true null hypotheses, 
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including the global null hypothesis. For the confirmatory clinical trials, strong control of FWER is 
typically necessary.  
However, if the multiplicity is over-controlled through an inefficient strategy, one would see a 
loss of power by excessive Type II error, or the need of increasing sample size more than what is 
realistically required. Therefore, rigorous, yet efficient, statistical planning at the design stage of a clinical 
trial, as well as for analyses, is crucial to the success of phase III confirmatory clinical trials. 
1.3 Overview of the Multiplicity Management Strategies  
There are many strategies in managing multiplicity that meet the requirement of strong control of 
Type I error, and they can generally be based on closed testing principles [7]. The closed testing 
procedure is a method for performing more than one hypothesis test simultaneously. Specifically, suppose 
there are 𝐾 hypotheses 𝐻1, …, 𝐻𝑘 to be tested with the overall Type I error rate α. The closed testing 
principle allows the rejection of any one of these elementary hypotheses 𝐻𝑖 if all possible intersection 
hypotheses involving 𝐻𝑖 can be rejected by valid local level α test. In this regard, closed testing 
procedures provide strong control of Type I error for all hypotheses and all possible intersections. 
Examples of closed testing procedures that are well known and have been used frequently for 
confirmatory clinical trials, as well as one that is less commonly used, are discussed in detail in this 
section. 
1.3.1 Hierarchical Methods 
One widely used closed testing method is based on hierarchical (or sequential) assessments for a 
pre-determined order for the hypotheses to be tested according to clinical priorities and/or statistical 
power. For this method, each hypothesis in the pre-determined order is assessed at level α(with the 
intersections of these hypotheses being the corresponding hypothesis or previous hypotheses in the order). 
The steps continue to the next successive test in the hierarchy if and only if rejections in all previous steps 
are observed. The formal testing stops at the first step where p > α, and all subsequent hypotheses are not 
rejected without formal testing. 
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1.3.2 Basic Bonferroni Procedure and Alpha Propagation Methods 
Alternatively, when a pre-determined order for two or more hypotheses is not clearly available, 
the well-known Bonferroni procedure can be useful to maintain strong control of Type I error; and it can 
have reasonable power (e.g., at least 0.80) when at least one assessment has much higher power than the 
others (with this scenario being potentially realistic for 2 to 5 assessments). For this closed testing 
method, each of the m individual hypotheses is tested at level α/m, where α is the pre-specified family-
wise Type I error rate (FWER). This procedure is very straightforward to implement, and it 
simultaneously addresses all intersections that pertain to each hypothesis to which it is applied. 
Other closed testing methods, also known as the alpha propagation methods that are based on the 
basic Bonferroni procedure, are widely used for confirmatory clinical trials. Examples are the Bonferroni-
Holm method [8], which is known as the step-down method, and the Hochberg method [9], which is also 
called the step-up method. Both of these methods are based on the ordering of the p-values from the 
hypothesis tests from the smallest p-value 𝑝(1) to the largest p-value 𝑝(𝑚). 
Accordingly, the Bonferroni-Holm method begins with testing the hypothesis corresponding to 
the smallest p-value at level α/m. If this hypothesis is rejected via 𝑝(1) < 𝛼/𝑚, then the second smallest 
p-value 𝑝(2)is assessed  at the level 𝛼/(𝑚 − 1). Testing continues at 𝛼/(𝑚 − 2), 𝛼/(𝑚 − 3), … , 𝛼 until 
there is either failure to reject a corresponding hypothesis (and thereby all subsequent hypotheses) or all 
hypotheses are rejected. The Hochberg method proceeds from the opposite direction. It starts with the 
largest p-value and tests it at level α. If this hypothesis is rejected via 𝑝(𝑚) < 𝛼, then all hypotheses are 
rejected. If 𝑝(𝑚) > 𝛼, testing proceeds to the second largest p-value at (𝛼/2) and then to the successively 
smaller p-values in the ordering at (𝛼/3),  … , (𝛼/𝑚) until the largest m* for which there is rejection via 
(𝑝(𝑚∗) < 𝛼/(𝑚 − 𝑚 ∗ +1)) where m* ≤ m (in which case all subsequently ordered hypotheses with 
smaller p-values are also rejected; or testing can end with no hypotheses being rejected).   
Comparing the rejection rules of the Bonferroni-Holm method and the Hochberg method, the 
Hochberg method is more powerful in terms of rejecting hypotheses. The underlying reason is that the 
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Hochberg method is derived from the more powerful Simes global test, which makes use of the joint 
distributions of the tests partially, where the Holm method is based on the basic Bonferroni procedure, 
and is a completely nonparametric procedure. Arranging the powers for the above testing procedures from 
the smallest to the largest, we have Bonferroni < Bonferroni-Holm < Hochberg.  
Whereas the Bonferroni-Holm method has general applicability, Hochberg’s method requires 
independent tests (or non-negatively correlated tests with an appropriate structure [10]). In this regard, 
Hochberg’s method can provide strong control of Type I error for the one-sided comparisons between test 
and control treatments for two non-negatively correlated endpoints for both the overall population of all 
patients and a pre-specified inferential subgroup. 
It also can be noted that the previously described hierarchical method and the strategies that are 
based on Bonferroni methods can be used individually or in combinations. 
1.3.3 Closed Testing Procedure through Multiway Averages 
Closed testing through multiway averages is another useful approach for managing multiplicity 
for one-sided comparisons between test and control treatments for endpoints [11], but it has been used 
less for current clinical trial planning. It features a global test that addresses a global null hypothesis 
concerning no differences between treatments for endpoints simultaneously, with the potential for testing 
all possible subsets for combinations of endpoints, including the respective separate endpoints, if certain 
requirements are met. The whole process provides strong control of FWER.  
The system of hypotheses is closed under intersection H = {Ho
I ≡ ⋂ Ho
k
k∈I : I ⊂ {1 … , r}}. It 
contains all marginal hypotheses of the 𝑟 separate endpoints. With this procedure, first, all 𝑟 are included 
in a global test of hypothesis at level α (since it corresponds to the intersection of all marginal endpoints 
hypotheses). If this global test rejects the global null hypothesis, then all the subsets of (𝑟 − 1) outcomes 
are tested using the same type of global test at level α. Next, subsets of (𝑟 − 2) endpoints are tested if and 
only if every hypothesis containing that subset has already been rejected. In other words, a hypothesis is 
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rejected if all higher-dimensional marginal hypotheses containing this hypothesis are also rejected.  For 
this procedure, every decision that leads to rejection of a hypothesis Ho
I  is controlled by α (Figure 1.1). 
This procedure implies that failure to reject a test at one step could rule out testing a group of hypotheses 
at later steps. It is possible that this closed testing procedure is stopped at an early stage before reaching 
the individual level of hypotheses. When this happens, the results can be difficult to interpret [12]. Some 
researchers claim that the outcomes found under this situation can be interpreted as a “syndrome” [11].    
The power of the closed testing procedure after a global test has been compared to several previously 
noted stepwise methods, such as the Bonferroni-Holm method, the Hochberg method, as well as ordering 
the endpoints in a special order and proceeding to test each endpoint in a sequential manner.  The closed 
testing methods have a slight advantage in power to reject the global hypothesis while the stepwise 
methods have a slight advantage to reject the individual hypotheses under certain simulation settings [12].  
 
Figure 1.1 Diagram of closed principle 
1.3.4 Adjusted P-values for Simultaneous Inference 
It has been proposed that results from simultaneous tests be reported as multiplicity adjusted p-
values, so that the adjusted p-value for an individual hypothesis can be compared directly with a chosen 
significance level α.  If it is less than or equal to α, then the hypothesis is rejected [13]. For the Bonferroni 
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procedure, the adjusted p-value is 𝑚 × 𝑝. It is (𝑚 − 𝑖 + 1) × 𝑝(𝑖) for the Bonferroni-Holm method with 𝑖 
indicating the order of the hypothesis test [13, 14].  For the closed testing procedure through multi-way 
averages, the adjusted p-value is the largest p-value among the individual hypothesis and all of the 
intersection hypotheses that involve this hypothesis [15] . 
1.4 Global Test  
Whereas the multiple testing procedures provide the open display of the data, a definitive, overall 
conclusion of the treatment efficacy might be of primary interest for the confirmatory clinical trial. One 
possible solution is to pre-specify a single primary endpoint in the study protocol, which represents the 
formal hypothesis, while putting other endpoints in secondary or exploratory roles rather than for formal 
interpretations. However, in many cases, choosing one endpoint over the others could be speculative, 
especially when handling multiple efficacy endpoints.  Thus, a single, overall, objective probability 
statement that addresses the question of whether or not the experimental therapy is efficacious is of 
importance.  
For the general specification, the following notations will be used in the following sections: 
𝑖 denotes treatment group, 𝑖 = 1, 2 
𝑗 denotes subject for the pooling of all subjects,  𝑗 =  1, 2, … , 𝑁 
𝑢 denotes subject within treatment group, 𝑢 = 1, 2, … , 𝑛𝑖 
𝑘 denotes endpoint, 𝑘 = 1, 2, … , 𝑟 
ℎ denotes stratum, ℎ = 1, 2, … , 𝑞 
𝑌𝑖𝑢𝑘 denotes the observed value of the 𝑘th endpoint for the 𝑢th subject for the 𝑖th treatment group 
𝑛𝑖 denotes the sample size in 𝑖th group 
𝑁 = (𝑛1 + 𝑛2) 
𝟏𝑟 is the (𝑟 × 1) vector of 1’s. 
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1.4.1 O’Brien’s Global Test 
O’Brien  proposed a construction of a class of multivariate test statistics for multiple endpoints 
with the consideration of showing treatment differences in the same direction under the clinical trial 
setting [16]. Specifically, single endpoints are summed through ordinary least squares (OLS) or weighted 
least squares (WLS), which leads to asymptotically normal statistics. In the case of uniformly 
equidirected alternatives, this approach is more powerful than the usual tests.   
Let 𝒀𝑖𝑢 = (𝑌𝑖𝑢1, … , 𝑌𝑖𝑢𝑟)
′, and let ?̅?𝑖 = (∑ 𝒀𝑖𝑢 𝑛𝑖⁄
𝑛𝑖
𝑢=1 ). Under the global null hypothesis 𝐻0 of 
no differences between treatments (in the sense that each patient would have the same values for all 
endpoints regardless of the randomly assigned treatments), 𝒅 = (?̅?1 − ?̅?2) would have its expected value 
as 𝜺(𝒅|𝐻0) = 0, and its known covariance matrix as 
𝑉𝑎𝑟(𝒅|𝐻0) = 𝑽𝒅,0 =
𝑁
𝑛1𝑛2(𝑁 − 1)
∑ ∑(𝒀𝑖𝑢 − ?̅?)(𝒀𝑖𝑢 − ?̅?)
′
𝑛𝑖
𝑢=1
2
𝑖=1
, 
where 𝑁 = (𝑛1 + 𝑛2) and ?̅? = (𝑛1?̅?1 + 𝑛2?̅?2) 𝑁⁄ . Accordingly, 𝒁 = 𝑫
−1𝒅 where 
𝑫 = 𝐷𝑖𝑎𝑔(√𝑣10, … , √𝑣𝑟0) for which the 𝑣𝑘0 are the diagonal elements of 𝑽𝒅,0 has 𝜀(𝒁|𝐻0) = 0 and 
𝑽𝒂𝒓(𝒁|𝐻0) = 𝑫
−1𝑽𝒅,0𝑫
−1 = 𝑽𝒁,0. In this regard, 𝒁 is the vector of standardized differences between 
treatments for the 𝑟 endpoints. For 𝒁, the ordinary least squares test statistic (with equal weights for the 𝑟 
endpoints) is 𝑇𝑂𝐿𝑆 = (𝟏𝑟
′ 𝒁) (𝟏𝑟
′ 𝑽𝒁,0𝟏𝑟)⁄
0.5
. When the sample sizes 𝑛1 and 𝑛2 are sufficiently large,  𝑇𝑂𝐿𝑆 
has an approximately normal distribution with expected value 0 and variance 1. Otherwise 𝑇𝑂𝐿𝑆 can have 
(essentially) exact assessment through enumeration (or simulation) of its randomization distribution (with 
respect to the 𝑁! (𝑛1! 𝑛2!)⁄  possible assignments of the 𝑁 patients to the two groups). A usual version of 
𝑇𝑂𝐿𝑆 pertains to the {𝑌𝑖𝑢𝑘} as ranks of the 𝑁 patients for the 𝑟 endpoints. An alternative test statistic to 
𝑇𝑂𝐿𝑆 is the weighted least squares criterion 𝑇𝑊𝐿𝑆 = (𝟏𝑟
′ 𝑽𝒁,0
−𝟏 𝒁) (𝟏𝑟
′ 𝑽𝒁,0
−𝟏 𝟏𝒓)⁄
0.5
; and it can have better 
power than 𝑇𝑂𝐿𝑆 when homogeneity applies to 𝒁 in the sense that 𝑄 = (𝒁 − 𝑔0𝟏𝑟)
′𝑽𝒁,0
−1 (𝒁 − 𝑔0𝟏𝑟), 
with 𝑔0 = (𝟏
′𝑽𝒁,0
−1 𝒁) (𝟏′𝑽𝒁,0
−1 𝟏)⁄  is not contrary to the chi-square distribution with (𝑟 − 1) degrees of 
freedom (d.f.).   
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A usual version of 𝑇𝑂𝐿𝑆 pertains to the {𝑌𝑖𝑢𝑘} as ranks of the 𝑁 patients for the 𝑘 endpoints. 
Specifically, let 𝑅𝑖𝑢𝑘 be the rank of 𝑌𝑖𝑢𝑘 among all values of the 𝑘th endpoints in the pooled group, and 
define 𝑆𝑖𝑢 as the sum of the ranks for each subject. Then a one-way analysis of variance on 𝑆𝑖𝑢, or 
alternatively a randomization based mean score test as an extension of a corresponding two-sample rank-
sum test, can be performed.   
Under the situation that all endpoints are equally correlated, i.e., correlation equals 𝜌, then 
formula 𝑇𝑊𝐿𝑆 becomes 
?̅?
{[1+(𝑟−1)𝜌]/𝑟}1/2
~𝑁(0,1)         
where 𝑧̅ is the mean of 𝑧1, 𝑧2, … , 𝑧𝑟. Thus two-sided 5% significance is achieved if 𝑧̅ > 1.96{[1 +
(𝑟 − 1)𝜌]/𝑟}1/2 , which decreases with 𝑟 and increases with 𝜌 [17]. For example, for 4 endpoints, if they 
are independent, say 𝜌 = 0, the critical value is 0.98; if they are perfectly dependent, i.e., 𝜌 = 1, the 
critical value is then 1.96 [2]. 
O’Brien’s approach provides a single overall test that is very sensitive to the departures from the 
null hypothesis of no treatment effect, if improvement is demonstrated consistently among the endpoints. 
Especially, in the situation that the sample size is relatively small compared to the number of endpoints, 
each individual test may fail to demonstrate the statistical significance, but the combined evidence from 
all endpoints can provide a convincing result. 
When the treatment effects are expected to occur in only a few measurements or the directions of 
differences cannot be anticipated in advance, the global test may not be the best approach for the analysis. 
1.4.2 Generalized Estimating Equations 
An extension of O’Brien’s global test includes the adaptation to binary endpoints [17]. Let 𝑝𝑘1, 
𝑝𝑘2be the proportions corresponding to either treatment for the 𝑘th binary outcome variable; ?̅?𝑘 =
(𝑝𝑘1𝑛1 + 𝑝𝑘2𝑛2)/𝑁.  
𝑧𝑘 =
𝑝𝑘1−𝑝𝑘2
[(?̅?𝑘(1−?̅?𝑘)𝑁/𝑛1𝑛2]1/2
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is asymptotically N(0,1) under the null hypothesis. The correlation between 𝑧𝑘 and 𝑧𝑘′, for 𝑘 ≠ 𝑘′is 
estimated by 
𝑠𝑘𝑘′−?̅?𝑘?̅?𝑘′
[?̅?𝑘?̅?𝑘′(1−?̅?𝑘)(1−?̅?𝑘′)]1/2
              
where 𝑠𝑘𝑘′ is the proportion of all patients with responses for both variables 𝑘 and 𝑘′. 
A generalization for the above mentioned approach is the use of generalized estimating equations 
(GEE), which takes the correlation among outcomes into consideration [2, 18]. With the assumption that 
the treatment has the same effect on all outcome measures, a Wald test statistic can be computed. This can 
be achieved through a standard SAS procedure. 
𝑙𝑜𝑔𝑖𝑡(𝜇𝑖𝑘) = 𝛼𝑘 + 𝛽𝑥𝑖 
𝛼𝑘 allows for a different control treatment favorable outcome occurrence rate for each of the endpoints, 
and 𝛽 is the common intervention effect. The GEE approach has the advantage of providing an odds ratio 
and its 95% confidence interval in addition to the p-values. 
1.4.3 Cox Model and the Wei-Lin-Weissfeld Method  
One way for handling time-to-event outcomes for a global test is to transform each of the 𝐾 time-
to-event outcomes with possible censoring to logrank scores [19, 20] and then implement a global test. 
These logrank scores are centered about zero, with starting point at 1 and decreasing as endpoints 
lengthen. However, a notable issue for this approach is that the differences between the logrank scores for 
treatment groups do not provide clinical meaningful interpretations.  
Hazard ratios provided by the Cox proportional hazards model are easy to interpret clinically. 
Under the multiple survival endpoints situation, a multivariate semiparametric method via the Cox model 
that can produce log hazard ratios and their covariance matrix that rely on the proportional hazard 
assumption, is known as the Wei-Lin-Weissfeld method [21]. For each endpoint, a marginal Cox 
proportional hazards model with the treatment indicator variable 𝑥𝑖 is fitted. The hazard function 𝜆𝑗𝑘(𝑡) 
for the failure time 𝑇𝑗𝑘 takes the form 
𝜆𝑗𝑘(𝑡, 𝑥𝑖) = 𝜆0𝑘(𝑡)exp {𝛽𝑘𝑥𝑖} 
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with 𝜆0𝑘(𝑡) as the underlying baseline hazard function for event 𝑘. 
Let 𝑹𝑖 = (𝑟𝑖1, … , 𝑟𝑖𝑟) be the (𝑛𝑖 × 𝑟)  matrix of dfbeta residuals for group 𝑖 obtained from the 
fitted unadjusted Cox model for each of the 𝑘 events, where the dfbeta residuals represent the 
approximate change in the log hazard ratio estimate when the 𝑗th individual is removed. For 𝑹 =
(𝑹𝟏
′ , 𝑹𝟐
′ )′, then ?̂? = 𝑹′𝑹 = (𝑹𝟏
′ 𝑹𝟏 + 𝑹𝟐
′ 𝑹𝟐) is the approximate covariance matrix for ?̂?, where ?̂? =
(?̂?1, … , ?̂?𝑟 )′ is the estimated log hazard ratio vector for test versus control group for the respective 
outcomes based on the Cox proportional hazards model [22, 23]. A model-averaged log hazard ratio can 
be estimated by 𝜃 = 𝑪′?̂?. 
The global test for comparing the average log hazard ratio to zero can then be constructed as  
𝑍 =
𝑪′?̂?
(𝑪′?̂?𝑪)𝟏/𝟐
 
with 𝑪 as 𝑪𝑾𝑳𝑾 = (𝟏𝑟
′?̂?−𝟏𝟏𝑟)
−𝟏?̂?−𝟏𝟏𝑟 for weighted average, or 𝑪𝒆𝒒𝒖 = 𝟏𝒓/𝑟 for equal weights. This 
test has an asymptotic normal distribution.  
1.4.4 Stratified Mann-Whitney Estimator 
When outcomes are strictly ordinal response variables, e.g. either ordered categories or 
continuous determinations that are not compatible with an interval scale, Mann-Whitney estimates are 
applicable particularly when the multivariate normal assumption is a concern or noteworthy outliers are 
present.  In addition, it is very common that a confirmatory clinical trial has a stratified design, for 
example, multicenter studies, and /or strata for baseline characteristics such as gender or disease severity. 
Stratified multivariate Mann-Whitney estimators can be more useful under such circumstances than the 
van Elteren test statistic. They have the ability of providing confidence intervals, having a multivariate 
extension to a set of 𝑘 outcomes, and handling possible missing data for one or more of the response 
variables assuming missing completely at random (MCAR) [24, 25]. 
Stratified multivariate Mann-Whitney estimators  ?̂? = (𝜉1̂, 𝜉2̂, … 𝜉?̂?)
′
= 𝑫?̂?𝟐
−1?̂?𝟏 , where ?̂?𝟏 =
(𝜃11, 𝜃12, … , 𝜃1𝑟), ?̂?𝟐 = (𝜃21, 𝜃22, … , 𝜃2𝑟) and 𝑫𝑎denotes a diagonal matrix with the element in vector 𝑎 
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on the diagonal, are constructed through several steps. Let 𝑆𝑗 denotes the stratum for patient j, and 𝑡𝑗 = 1 
if 𝑖=1, and 𝑡𝑗 = −1 if 𝑖=2. 𝑍𝑗𝑘 indicates whether the response for 𝑗th subject and 𝑘th outcome is missing 
(set to 1 if it is not missing, and 0 otherwise). Then  𝜃1𝑘 =
1
𝑁(𝑁−1)
∑ ∑ 𝑈1𝑗𝑗′𝑘
𝑁
𝑗≠𝑗′
𝑁
𝑗=1 , which pertains to the 
probability that a random pair of patients is from the same stratum and has a patient in group 1 with a 
larger value for the 𝑘th response variable than the other patient in group 2, with tie breaks at probability 
0.5; 𝜃2𝑘 =
1
𝑁(𝑁−1)
∑ ∑ 𝑈2𝑗𝑗′𝑘
𝑁
𝑗≠𝑗′
𝑁
𝑗=1 , which pertains to the probability that a random pair of patients is 
from the same stratum with different treatments and non-missing values of the response for endpoint 𝑘 for 
both patients. In this construction, 
 𝑈1𝑗𝑗′𝑘 = 𝐼{(𝑆𝑗 − 𝑆𝑗′) = 0} × [𝐼{(𝑡𝑗 − 𝑡𝑗′)(𝑌𝑗𝑘 − 𝑌𝑗′𝑘)𝑍𝑗𝑘𝑍𝑗′𝑘 > 0} + 0.5 × 𝐼 {(𝑡𝑗 − 𝑡𝑗′)
2
𝑍𝑗𝑘𝑍𝑗′𝑘 >
0} × 𝐼{(𝑌𝑗𝑘 − 𝑌𝑗′𝑘) = 0}] /(𝑛𝑗𝑘 + 𝑛𝑗′𝑘 + 1),  
𝑈2𝑗𝑗′𝑘 = 𝐼{(𝑆𝑗 − 𝑆𝑗′) = 0} × 𝐼 {(𝑡𝑗 − 𝑡𝑗′)
2
𝑍𝑗𝑘𝑍𝑗′𝑘 > 0} /(𝑛𝑗𝑘 + 𝑛𝑗′𝑘 + 1).  
𝐼(𝐴) has the value 1 if the condition 𝐴 is satisfied or the value 0 if otherwise, and 𝑌𝑗𝑘 = 0 when 𝑍𝑗𝑘 = 0 
without loss of generality; 𝑛𝑗𝑘 denotes the sample size for the 𝑘th response variable for patients with the 
same stratum and treatment group as the 𝑗th patient. 
A consistent estimator for the covariance matrix for ?̂? is 𝑽?̂? = 𝑫?̂?[𝑫?̂?𝟏
−1, −𝑫?̂?𝟐
−1]𝑉?̅?[𝑫?̂?𝟏
−1, −𝑫?̂?𝟐
−1]𝑫?̂?, 
where𝑭𝑗 = (𝑼𝟏
′ , 𝑼𝟐
′ )′,  ?̅? = (?̂?𝟏′, ?̂?𝟐′)
′, and 𝑉?̅?=
4
𝑁(𝑁−1)
∑ (𝑭𝒋 − ?̅?)(𝑭𝒋 − ?̅?)′
𝑵
𝒋=𝟏 . 
With certain transformations, the above stratified Mann-Whitney estimator for the 𝑘th outcome 
can have an expression that is comparable to the stratified extension of the Wilcoxon rank sum statistics 
of van Elteren [25]. The sum of  𝑈1𝑗𝑗′𝑘 for stratum h has the expression (𝑛ℎ1𝑘𝑛ℎ2𝑘𝜉ℎ𝑘)/(𝑛ℎ1𝑘 + 𝑛ℎ2𝑘 +
1)𝑁(𝑁 − 1), where 𝜉ℎ𝑘is the Mann-Whitney estimator for the probability that a randomly selected 
patient in group 1 has a larger value for the kth outcome than a randomly selected patient from group 2 in 
ℎth stratum; and sum of 𝑈2𝑗𝑗′𝑘 for the same stratum has the expression (𝑛ℎ1𝑘𝑛ℎ2𝑘)/(𝑛ℎ1𝑘 + 𝑛ℎ2𝑘 +
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1)𝑁(𝑁 − 1)and so 𝜉𝑘 = (∑ 𝑤ℎ𝑘?̂?ℎ𝑘
𝑞
ℎ=1 / ∑ 𝑤ℎ𝑘
𝑞
ℎ=1 ) is the stratified Mann-Whitney estimator for the 𝑘th 
response variable, where 𝑤ℎ𝑘 = (𝑛ℎ1𝑘𝑛ℎ2𝑘)/(𝑛ℎ∗𝑘 + 1) and 𝑛ℎ∗𝑘 = (𝑛ℎ1𝑘 + 𝑛ℎ2𝑘).  
When the sample size is large enough, e.g., 𝑛+𝑖𝑘 ≥ 50, and all 𝑛ℎ𝑖𝑘 ≥ 4, where 𝑛+𝑖𝑘 =
∑ 𝑛ℎ𝑖𝑘
𝑞
ℎ=1 , ?̂? has an approximately multivariate normal distribution. Thus, the estimate of the overall 
treatment effect is 𝑪′?̂?, and the two-sided 100×(1-2α)% confidence interval for 𝑪′?̂?, with 𝑪′ =
(𝑐1, 𝑐2, … , 𝑐𝑟) is 𝑪′?̂? ± 𝑧𝛼√𝑪′𝑽?̂?𝑪, where 𝑧𝛼 is the 100×(1-α) percentile of the standard normal 
distribution. For the average across all outcomes, 𝑪 = 𝟏𝑟/𝑟. 
Assuming MCAR, missing responses can be handled with several approaches [24, 26]. Besides 
what has been provided above, one method manages missing values as tied with all other values in the 
same stratum. Another choice is the last observation carried forward (LOCF) based on the kernels of the 
U-statistics, or the observed value of 𝑌. Or, complete cases analyses is possible where patients with 
missing values are removed. 
A R package that has all the features for the discussed approaches for the implementation of 
stratified multivariate Mann-Whitney estimators is readily available and straightforward to use [26].  
1.5 Handling Baseline Imbalance in Clinical Trials 
Analysis of Covariance (ANCOVA) is a standard statistical approach that has been used to assess 
the relationship between an outcome and a variable when other variables are present. This approach is 
desirable when 1) the differences among comparison groups need to be adjusted so that bias may be 
reduced, 2) to increase power of the statistical test through variance reduction, therefore producing 
narrower confidence intervals, 3) to correct the imbalance for the baseline variables between comparison 
groups that are due to randomization, 4) to clarify whether the significant relationship between outcome 
and the variable is true or because of confounding factors, and 5) to verify whether the findings are 
uniform across subpopulations, or the treatment effects differ by subpopulation through the invocation of 
interaction [27].  
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The application of conventional parametric ANCOVA is through modeling, for example, linear 
regression model, logistic regression model, or Cox proportional hazard model, which relies on the 
statistical assumptions. In the settings of clinical trials, however, all analyses should have a priori 
specification in order to preserve the validity of the results, whereas the assumptions of the parametric 
ANCOVA are unverifiable. This dilemma led to the development of nonparametric randomization based 
ANCOVA for randomized clinical trials. 
1.5.1 Nonparametric Randomization Based ANCOVA 
Details for the methodology of nonparametric ANCOVA can be found in several published 
papers [28, 29]. Briefly, this approach is based on weighted least squares methods to analyze the 
differences between treatment groups while simultaneously restricting the differences in the covariates 
among treatment groups to be zero (i.e., correcting the imbalance). Specifically, let 
𝒙𝒊𝒖 = (𝑥𝑖𝑢1, … , 𝑥𝑖𝑢𝑚)′, denote the vector of 𝑀 covariables for the 𝑢th patient on treatment 𝑖. Then the 
sample mean of the response and sample mean of the covariables with respect to treatment 𝑖 are written as 
?̅?𝑖 =
1
𝑛𝑖
∑ 𝑦𝑖𝑢
𝑛𝑖
𝑢=1 , and ?̅?𝑖 =
1
𝑛𝑖
∑ 𝑥𝑖𝑢
𝑛𝑖
𝑢=1 . Let 𝒇 = (𝑑𝑦, 𝒅𝒙
′ )′ where 𝑑𝑦 = (?̅?1 − ?̅?2), and 𝒅𝑥 = (?̅?1 − ?̅?2). In 
this sense, 𝒇 is a vector that contains the differences in mean response and means for the covariates 
between the two groups. In a randomized trial, the expected value for 𝒅𝑥 would in fact be equal to zero. 
There are two ways to generate the covariance matrix for 𝒇. Under the null hypothesis of no treatment 
difference, the variance-covariance matrix 𝑽𝟎 is as follows:  
𝑽𝟎 =
𝑁
𝑛1𝑛2(𝑁 − 1)
∑ [
(𝑦∗𝑗 − ?̅?∗∗)
2 (𝑦∗𝑗 − ?̅?∗∗)(𝒙𝑗 − ?̅?∗)′
(𝑦∗𝑗 − ?̅?∗∗)(𝒙𝑗 − ?̅?∗)′ (𝒙𝑗 − ?̅?∗)(𝒙𝑗 − ?̅?∗)′
]
𝑁
𝑗=1
 
Here ?̅?∗∗ = ∑ 𝑦∗𝑗/𝑁
𝑛
𝑗=1  is the sample mean of the response variable for all patients in the trial under the 
null hypothesis, and 𝑦∗𝑗 is the response under the null hypothesis for patient 𝑗 regardless of treatment 
assignment. ?̅?∗ = ∑ 𝒙𝑗/𝑁
𝑛
𝑗=1  is the sample mean vector for the covariables for all patients in the trial, and  
𝒙𝑗 is the vector of covariables for patient 𝑗.  
The other strategy for the estimated covariance matrix 𝑽𝒔 of 𝒇 uses the estimator 
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𝑽𝒔 = ∑
1
𝑛𝑖(𝑛𝑖 − 1)
2
𝑖=1
∑ [
(𝑦𝑖𝑢 − ?̅?𝑖)
2 (𝑦𝑖𝑢 − ?̅?𝑖)(𝒙𝑖𝑢 − ?̅?𝒊)′
(𝑦𝑖𝑢 − ?̅?𝑖)(𝒙𝑖𝑢 − ?̅?𝒊)′ (𝒙𝑖𝑢 − ?̅?𝒊)(𝒙𝑖𝑢 − ?̅?𝒊)′
]
𝑛𝑖
𝑢=1
 
This is under the assumption that the trial patients are a simple random sample from a very large 
population. 𝑽𝒔 allows population-based inference after covariance adjustment. 𝑽 can be further 
partitioned as 𝑽 = [
𝑽𝒚𝒚 𝑽𝒚𝒙′
𝑽𝒚𝒙 𝑽𝒙𝒙
]. 
A linear model 𝒇 = 𝒁𝑏 can be fit using the weighted least squares method to determine b, where 
𝒁 = (𝟏 𝟎𝒑
′ )′, with 𝟎𝑝 denoting a (px1) vector of 0’s, and b represents the adjusted mean difference for the 
response. Determination of b can be obtained as (𝒁′𝑽−𝟏𝒁)−𝟏𝒁′𝑽−𝟏𝒇 = 𝑑𝑦 − 𝑽𝒚𝒙′𝑽𝒙𝒙
−𝟏𝑑𝑥 , where 𝑽 is 
either 𝑽𝟎 or 𝑽𝒔. An estimator of its covariance matrix is 𝑉𝑏 = (𝒁′𝑽
−𝟏𝒁)−𝟏 = 𝑽𝒚𝒚 − 𝑽𝒚𝒙′𝑽𝒙𝒙
−𝟏𝑽𝒚𝒙. This 
estimator is the exact variance of the randomization distribution of b when 𝑽𝟎is used; when 𝑽𝒔 is used 
instead, it corresponds to a consistent estimator of the variance of b. 
When sample sizes are sufficiently large, i.e., 𝑛𝑖 ≥ 15√𝑀 + 1, 𝑄𝑏 = 𝑏
2/𝑉𝑏 has an approximate 
chi-square distribution with one degree of freedom. With 𝑉𝑏based on 𝑽𝒔 , a confidence interval for the 
mean difference of the response can be obtained. When sample sizes are not large, the assessment of b is 
possible through an exact p-value from the randomization distribution that uses 𝑽𝟎. 
The main consideration for this method is that there is a valid randomization to the treatment 
groups so that the distributions of the covariables are statistically similar across the two treatment groups.  
1.5.2 Stratified Studies and Multivariate Responses 
The aforementioned nonparametric ANCOVA also has useful extensions for stratified studies 
[29, 30] and multivariate responses[29]. When independent randomization is conducted at a stratum level, 
analysis for the combined strata based on moderately large sample size (𝑛ℎ𝑖 ≥ 15√𝑀 + 1) is then 
conducted as ?̅? = ∑ 𝑤ℎ
𝑞
ℎ=1 𝑏ℎ, , and the variance estimator 𝑉?̅? = ∑ 𝑤ℎ
2𝑞
ℎ=1 𝑣𝑏ℎ, where 𝑏ℎ and 𝑣𝑏ℎare the 
counterparts of b and 𝑣𝑏 within stratum h, and 𝑤ℎ is the standardized weight for the hth stratum such that 
∑ 𝑤ℎ = 1
𝑞
ℎ=1 . Then 𝑄?̅? = ?̅?
2/𝑉?̅? is an approximately chi-square test statistic (d.f.=1) for comparing the 
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two treatments with adjustment for both covariables and strata. When the sample sizes are not large for all 
strata, covariance adjustment is applied after stratification adjustment rather than within each stratum. 
If multiple responses are to be analyzed based on a stratified design, the construction of the test statistic is 
𝑄𝐴?̅? = ?̅?
′𝐴′{𝐴𝑉?̅?𝐴
′}−1𝐴?̅?, where A=𝟏𝑟
′ ,denotes a (𝑟 × 1) vector of 1’s, ?̅? and 𝑉?̅? are calculated with 
modified 𝑍 = [𝐼𝑟, 0𝑟𝑃′]′, which has approximately the chi-square distribution with d.f.=1. For this 
version, 𝑄𝐴?̅? is a stratified and covariance adjusted counterpart to the OLS method of O’Brien for 
multiple endpoints.   
1.5.3 Dichotomous, Ordinal and Survival Outcomes 
The nonparametric randomization based ANCOVA method can also have extensions to various 
types of response variables. For the dichotomous outcome, the sample mean of the responses for each 
treatment can be calculated as proportion 𝑝 and then transformed to 𝑙𝑜𝑔𝑖𝑡(𝑝)  =  𝑙𝑜𝑔(
𝑝
1−𝑝
) naturally. So 
the vector of differences 𝒇 can be created to include the differences in the log odds, which can be 
interpreted easily later as odds ratios, and the differences in the means of the covariables between two 
treatment groups. The weighted least squares method can then have application [29, 31]. When the 
outcome is ordinal, one approach is to expand the vector 𝒇 to accommodate the cumulative logits. 
Analysis can proceed as described previously with a multivariate extension of the covariance matrix. 
Alternatively, Mann-Whitney estimators with 𝒇 = (?̂?, 𝒅𝒙
′ ) and the weighted least squares approach can be 
useful [24]. The transformation to the Logrank scores is applicable for the survival outcome for treatment 
1 and 2 [31], or a hybrid method with the Cox proportional hazards model that only contains a treatment 
indicator can use the weighted least squares method with the log hazard ratio that compares treatment and 
placebo group as the response difference in the vector 𝒇.  The subsequent statistics can be constructed in a 
similar way [23]. 
1.6 Innovative Applications  
Multiplicity problems can be one dimensional, which means they come from only one source. For 
example, testing multiple efficacy endpoints at one time point, or evaluating a single endpoint repeatedly 
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at multiple visits. While the main purpose for those trials normally is to prove the overall treatment 
efficacy, it is of particular interest to identify which of the endpoints are significant, or which of the visits 
carry the significant effect.  
In this section, two examples are presented to illustrate the application of the multiway average 
closed testing procedure under those situations. The first example has four ordered categorical response 
variables at the four post-baseline visits, and they pertain to the comparison of two randomized treatments 
for a respiratory disorder. The second example discusses a randomized stroke clinical trial that has four 
efficacy outcomes for the comparison of a test treatment and placebo. The primary interest of the trial was 
to test the outcomes collectively to determine the overall treatment efficacy, then step down to see the 
efficacy of the individual outcomes.       
1.6.1 Global Test 
More generally, both 𝑇𝑂𝐿𝑆 and 𝑇𝑊𝐿𝑆 are applicable to a multivariate set of 𝑟 estimates ?̂? for 
multiple comparisons between two treatments for multiple endpoints for one or more populations. For 
example, ?̂? can be a set of estimates of mean differences between the test treatment and control group for 
a set of continuous endpoints. In this paradigm, when the underlying sample sizes are sufficiently large 
for ?̂? to have an approximately multivariate normal distribution with asymptotic expected value 𝜀𝐴(?̂?) =
𝜷 and an essentially known covariance matrix 𝑽𝜷 through a consistent estimator 𝑽?̂?, then 𝑇𝑂𝐿𝑆 =
(𝟏𝒓
′ ?̂?) (𝟏𝒓
′ 𝑽?̂?𝟏𝒓)
0.5
⁄  has an approximately normal distribution with expected value 0 and variance 1 
under the global null hypothesis H0: β = 0. Similar considerations apply to 
𝑇𝑊𝐿𝑆 = (𝟏𝒓
′ 𝑽?̂?
−𝟏?̂?) (𝟏𝒓
′ 𝑽?̂?
−𝟏𝟏𝒓)
0.5
⁄ . Also, if homogeneity applies to β in the sense that 𝛽 = 𝟏𝑟𝛿, then 
𝑇𝑂𝐿𝑆 pertains to 𝜀𝐴(𝟏𝒓
′ ?̂?) = 𝑟𝛿 and 𝑇𝑊𝐿𝑆 pertains to (𝟏𝒓
′ 𝑽?̂?
−𝟏𝟏𝒓) 𝛿 = 𝜀𝐴 (𝟏𝒓
′ 𝑽?̂?
−𝟏?̂?). 
1.6.2 Multiple Testing Strategy 
A global test using the OLS strategy will be performed on the combined endpoints as the OLS 
average of all endpoints.   
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𝑇𝑂𝐿𝑆 = (𝑪
′?̂?)/(𝑪′?̂?𝜷𝑪)
𝟏/𝟐 ~ 𝑁 (0, 1) 
where ?̂? is the vector of estimates for the comparisons, 𝑽?̂? is the estimated covariance matrix of ?̂?, and 
𝑪 = 𝟏𝑟
′ . 
When the global test is rejected, a closed testing procedure is conducted to identify whether there 
is statistical significance in each of the subsets of endpoints through their OLS combined criterion, or the 
individual endpoints, at a predefined α level. As an illustration, if there is a set of 4 endpoints, 𝐻1, 𝐻2, 𝐻3, 
and 𝐻4 represent null hypotheses for the separate endpoints; and the closed family contains 15 hypotheses 
representing all possible intersections of 𝐻1, 𝐻2, 𝐻3, and 𝐻4. Each member of the closed family can be 
viewed as a global hypothesis and therefore can be tested using a global test with corresponding 𝑪. For 
example, when testing the hypothesis corresponding to the intersection of the first two comparisons, the 
contrast matrix will be 𝑪 = (1,1,0,0). 
P-values for the hypothesis tests in this closed testing procedure are reported as multiplicity 
adjusted p-values. Specifically, results from a hypothesis and all of the other intersection hypotheses that 
imply this hypothesis are combined and the corresponding adjusted p-values are computed as the largest 
p-value among the p-values for the hypothesis and all the intersection hypotheses that imply it [15]. In 
this sense, if the adjusted p-value for an individual hypothesis test is less than the chosen significance 
level α, then the hypothesis is rejected. 
1.6.3 Randomized Respiratory Disorder Trial with Four Visits  
This example comes from a randomized clinical trial that compares a test treatment to placebo for 
a respiratory disorder. The listing of the data were published previously [6]. This trial had 111 patients 
from two centers, a baseline visit and four post-baseline visits that recorded patient global ratings of 
symptom control through a set of 5-category ordinal response variables as excellent, good, fair, poor and 
terrible. No missing values were observed in this example. 
It would be ideal to pre-define a visit when the treatment effect is at its maximum, and have the 
endpoint tested at that visit. However, such information may not be available a priori. Since it can be 
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expected that the treatment effects are in the same direction for each of the post-baseline visits, evaluating 
the global effect as the average of several visits, and then stepping down to see the individual visits seems 
to be a reasonable approach.  
GEE for a proportional odds model was used to account for the four repeated measures of the 
global ratings of symptom control. The model included center, baseline ratings of symptom control, 
treatment group, visit, and treatment group by visit interaction as explanatory variables. Estimates for 
odds ratios for the treatment differences at each of the post-baseline visits and their covariance matrix 
were then provided by the model. For this case, the OLS global test shows p-value < 0.0001 (Table 1.1), 
which warrants the invocation of the subsequent closed testing procedure for the subsets of the OLS 
averages of the endpoints. Since all subsets of the tests, 3-way and 2-way averages, are significant, this 
strategy enables the validity of testing each of the single endpoints at a pre-specified one-sided α level 
0.025 and preserves the FWER at this level in a strong sense.  
 
Contrast Matrix Estimate Variance 
Odds 
Ratio 
P-value 
(one-
sided) 
Multiplicity 
Adjusted 
P-value 
4-way Average (1,1,1,1)/4 1.18 0.078 3.25 <0.0001 <0.0001 
3-way Average 
(1,1,1,0)/3 1.24 0.083 3.45 <0.0001 <0.0001 
(1,1,0,1)/3 1.14 0.077 3.12 <0.0001 <0.0001 
(1,0,1,1)/3 1.00 0.078 2.71 0.0002 0.0002 
(0,1,1,1)/3 1.34 0.097 3.82 <0.0001 <0.0001 
2-way Average 
(1,1,0,0)/2 1.21 0.086 3.35 <0.0001 <0.0001 
(1,0,1,0)/2 1.00 0.083 2.71 0.0003 0.0003 
(1,0,0,1)/2 0.85 0.076 2.33 0.0011 0.0011 
(0,1,1,0)/2 1.51 0.110 4.53 <0.0001 <0.0001 
(0,1,0,1)/2 1.36 0.100 3.90 <0.0001 <0.0001 
(0,0,1,1)/2 1.15 0.109 3.16 0.0002 0.0002 
Single 
Endpoint 
(1,0,0,0)-Visit 1 0.69 0.098 2.00 0.0132 0.0132 
(0,1,0,0)-Visit 2 1.72 0.132 5.61 <0.0001 <0.0001 
(0,0,1,0)-Visit 3 1.30 0.141 3.66 0.0003 0.0003 
(0,0,0,1)-Visit 4 1.00 0.131 2.72 0.0029 0.0029 
Table 1.1 Respiratory disorder trial results  
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1.6.4 Randomized t-PA Stroke Trial with Multiple Outcomes 
The National Institute of Neurological Disorders and Stroke (NINDS) has defined the treatment 
success of acute stroke as “consistent and persuasive difference” in the proportion of patients achieving 
favorable outcomes on the Barthel Index, Modified Rankin Scale, Glasgow Outcome Scale, and National 
Institutes of Health Stroke Scale. The consensus was:  by categorizing outcomes as favorable / 
unfavorable, outcomes are more clinically meaningful; a single outcome would not provide sufficient 
evidence of efficacy for stroke, thus a global test is appropriate [2]. Accordingly, the NINDS t-PA stroke 
trial was analyzed with a global test as the trial’s primary objective, and accompanied by secondary tests 
of individual outcomes (published results are quoted in Table 1.2).  GEE was used to take the correlations 
among outcomes into account for the global test. 
The reported strategy for controlling multiplicity in this t-PA stroke trial was to test the global 
hypothesis first at the α level 0.05; if statistical significance was observed, then testing proceeded to the 
four individual outcomes and with each outcome tested at α level 0.05. However, this strategy does not 
meet the strong control of FWER. Therefore, a re-analysis of the trial was performed based on the 
published results.  
Because of the unavailability of patient level data, the covariance matrix for the GEE model β 
estimates was estimated in the following steps: assuming common correlation between each pair of the 
outcomes,  
𝜌 =
16𝑉?̅? − ∑ 𝑉?̂?𝑖
4
𝑖=1
∑ ∑ √𝑉?̂?𝑖𝑉?̂?𝑗
4
𝑗=1
4
𝑖=1,𝑖≠𝑗
 
where 𝑉?̂?𝑖 = (
log (𝑂𝑅 𝑢𝑝𝑝𝑒𝑟/𝑙𝑜𝑤𝑒𝑟)
1.96×2
)2 , 𝑖 = 1, 2, 3, 4, are the variances of the β estimates for the individual 
outcomes that can be computed from Table 2; 𝑉?̅? is the variance of the β estimate for the global test. The 
covariance for each outcome pair can then be computed as 𝑐𝑜𝑣(𝛽𝑖, 𝛽𝑗) = 𝜌 × √𝑉?̂?𝑖𝑉?̂?𝑗, where 𝑖 ≠ 𝑗. The 
calculated 𝜌 = 0.87. 
22 
 
Outcome 
Odds 
Ratio 
95% CI 
Barthel 1.63 1.06 2.49 
Modified Rankin 1.68 1.09 2.59 
Glasgow 1.64 1.06 2.53 
NIH Stroke Scale 1.72 1.05 2.84 
Global 1.73 1.16 2.6 
Table 1.2 Published t-PA stroke results. 
Since the global test for the OLS average met the required significance at one-sided 0.025 level 
(p-value=0.013), the closed testing procedure is performed for the subsets of the hypotheses, until the 
single endpoint level tests (Table 1.3). For this example, treatment efficacy applies for each of the single 
outcomes at the one-sided significance level 0.025.  
Contrast Matrix Estimate Variance 
Odds 
Ratio 
P-value 
(one-
sided) 
Multiplicity 
Adjusted 
P-value 
4-way Average (1,1,1,1)/4 0.51 0.053 1.67 0.0129 0.0129 
3-way Average 
(1,1,1,0)/3 0.50 0.051 1.65 0.0135 0.0135 
(1,1,0,1)/3 0.52 0.054 1.68 0.0129 0.0129 
(1,0,1,1)/3 0.51 0.054 1.66 0.0141 0.0141 
(0,1,1,1)/3 0.52 0.054 1.68 0.0128 0.0129 
2-way Average 
(1,1,0,0)/2 0.50 0.052 1.65 0.0138 0.0138 
(1,0,1,0)/2 0.49 0.052 1.64 0.0159 0.0159 
(1,0,0,1)/2 0.52 0.056 1.67 0.0148 0.0148 
(0,1,1,0)/2 0.51 0.053 1.66 0.0137 0.0137 
(0,1,0,1)/2 0.53 0.056 1.70 0.0128 0.0129 
(0,0,1,1)/2 0.52 0.057 1.68 0.0147 0.0147 
Single Endpoint 
(1,0,0,0)- Barthel 0.49 0.056 1.63 0.0191 0.0191 
(0,1,0,0)- Modified Rankin 0.52 0.056 1.68 0.0144 0.0144 
(0,0,1,0)- Glasgow 0.49 0.057 1.64 0.0188 0.0188 
(0,0,0,1)- NIH Stroke Scale 0.54 0.065 1.72 0.0165 0.0165 
Table 1.3 Re-analysis of the t-PA stroke trial 
1.7 Summary of Research 
The following chapters outline the innovative applications of a closed testing procedure for the 
control of multiplicity through multiway averages under various clinical trial designs.  
23 
 
Many confirmatory randomized clinical trials come with a stratified design. In addition, when the 
trial has random baseline imbalances, missing values, and strictly ordinal responses together with multiple 
endpoints, having an approach in place that can address multiplicity and solve other problems collectively 
and comprehensively is essential. A strategy is provided in Chapter 2 through a realistic case analysis.     
When two sources of multiplicity need to be managed simultaneously in one confirmatory clinical trial, 
the situation becomes complex and very challenging [32]. An example of such a situation is when the trial 
is focused on making primary inference on the overall population and/or some pre-specified subgroups, 
while multiple primary endpoints or key secondary endpoints are examined in each of the populations [4]. 
Chapter 3 proposes a strategy based on an innovative application of the closed testing procedure with 
multiway averages to address this complex multiplicity situation, and it applies this strategy to a real 
phase III confirmatory clinical trial. In addition, a simulation study is conducted based on this trial to 
compare the power of the proposed strategy to some more traditional alternative approaches.  
When two or more sources of multiplicity exist in one confirmatory clinical trial, the control of 
the FWER is even more complex. For a clinical trial that is designed to have efficacy assessed with 
multiple primary endpoints, for multiple dose groups, and at two or more post baseline visits, the 
objective is to have primary inference on all endpoints for at least one dose at any one of the visits. Under 
this situation, the prevailing multiplicity adjustment approaches through a fixed sequential testing 
procedure combined with the Hochberg approach normally emphasizes the evaluation of the higher dose 
than the lower dose, with the consideration that the higher dose is generally more efficacious. However, 
the higher dose may be associated with more safety concerns than the lower dose. A real confirmatory 
clinical trial is provided in Chapter 4 as an example to illustrate the considerations with such a design. 
One proposed strategy is a closed testing procedure combined with a sequential testing procedure. An 
alternative strategy is a closed testing procedure under a parallel gate keeping framework for this complex 
situation. Both strategies manage the higher dose and the lower dose equally and evaluate the multiple 
endpoints at multiple visits collectively. A simulation study is performed to evaluate the power of the 
proposed strategy. 
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Random baseline imbalances may happen in clinical trials together with the multiplicity issues. 
Conventional parametric ANCOVA is through modeling. However, for clinical trials, all analyses should 
be pre-specified, but the assumptions of the parametric ANCOVA are unverifiable. Also, when efficacy 
data are collected at multiple visits, subjects without post-baseline measurements are normally excluded 
from the longitudinal model that adjusts for baseline as covariate. With the application of nonparametric 
randomization-based ANCOVA (NPANCOVA), baseline is adjusted through a nonparametric approach. 
In addition, information from subjects who have only baseline values can be included. Moreover, the 
multiplicity strategy will be integrated to NPANCOVA. A future research direction and plan are stated in 
Chapter 5.  
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CHAPTER 2 : ANALYZING MULTIPLE ENDPOINTS  
– an Approach that Addresses Stratification, Missing Values, Baseline Imbalance and Multiplicity for 
Strictly Ordinal Outcomes 
2.1 Introduction 
Multiplicity commonly arises in clinical trials when the effect of the test treatment is evaluated in 
multiple ways. For example, when no single endpoint describes all dimensions of the effect of the test 
treatment, multiple efficacy endpoints are present. The main concern for the multiplicity problem in the 
Phase III confirmatory clinical trial is that insufficiently controlled multiple assessments lead to multiple 
opportunities for the findings of a clinical trial to be due to chance. Without appropriate control, the trial 
loses its validity because of the inflation of Type I error. For the confirmatory clinical trial, strong control 
of family-wise (or the experiment-wise) Type I error rate (FWER) is typically necessary. 
Besides multiplicity, the efficacy endpoints may also be strictly ordinal response variables, e.g. 
either ordered categories or continuous determinations that are not compatible with an interval scale. In 
addition, it is very common for confirmatory clinical trials to have a stratified design, for example, 
multicenter studies or according to baseline characteristics such as gender or disease severity, etc. 
Moreover, when comparing a test treatment to a control group, random baseline imbalances could occur. 
Also, missing values occur regardless how much effort has been involved in preventing them. When all 
those issues occur together in a single confirmatory clinical trial, controlling multiplicity while addressing 
all other issues simultaneously is not straightforward. 
For the strictly ordinal response variables, Mann-Whitney estimates are applicable, particularly 
when the multivariate normal assumption is a concern or noteworthy outliers are present.  Stratified 
multivariate Mann-Whitney estimators can be very useful for the stratified design. It has the ability of 
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providing confidence intervals, having a multivariate extension to a set of 𝑟 outcomes, and handling 
possible missing data for one or more of the response variables assuming missing completely at random 
(MCAR) or other paradigms [1, 2]. In the case of potential concern for random baseline imbalance, 
nonparametric randomization-based covariance adjustment [3, 4] can have pre-specified invocation for 
the estimators by expanding the Mann-Whitney estimator vector to include the stratified differences 
between means of covariables, producing a consistent estimator of the corresponding covariance matrix 
and then constraining the differences for covariables to 0’s [1].    
Closed testing through multiway averages can be a very useful approach in managing multiplicity 
[5], but it has been used less in the current clinical trial planning. It features a global test that addresses a 
global null hypothesis concerning treatment efficacy through a combination of endpoints, with the 
possibility for testing all possible subsets for combinations of endpoints, including the respective separate 
endpoints, if certain requirements are met. The whole process is under the strong control of FWER.  
For this paper, we illustrate combining stratified multivariate Mann-Whitney estimators for which 
randomization-based covariance adjustment is possible with the novel application of the closed testing 
procedure through multiway averages, and we develop an effective approach that is straightforward to 
implement and can additionally address missing data for some outcomes. 
2.2 Methods 
2.2.1 Stratified Multivariate Mann-Whitney Estimator  
Let ℎ =  1, 2, … , 𝑞 index a set of strata within which patients have randomization to two 
treatment groups indexed by 𝑖 =  1, 2. Let 𝑘 =  1, 2, … , 𝑟 index the response variables, and 𝑗 =
 1, 2, … , 𝑁 index the patients for the pooling of all patients regardless of their treatment group or strata. 
𝑌𝑗𝑘 denotes the response for the 𝑗th patient with 𝑘th strictly ordinal response. Stratified multivariate 
Mann-Whitney estimators  ?̂? = (𝜉1̂, 𝜉2̂, … 𝜉?̂?)
′
= 𝑫?̂?𝟐
−1?̂?𝟏 , where ?̂?𝟏 = (𝜃11, 𝜃12, … , 𝜃1𝑟), ?̂?𝟐 =
(𝜃21, 𝜃22, … , 𝜃2𝑟) and 𝑫𝑎 denote a diagonal matrix with the element in vector 𝑎 on the diagonal, are 
constructed through several steps. Let 𝑆𝑗 denote the stratum for patient 𝑗, and 𝑡𝑗 = 1 if 𝑖=1, and 𝑡𝑗 = −1 if 
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𝑖=2. 𝑍𝑗𝑘 indicates whether the response for 𝑗th subject and 𝑘th outcome is missing (set to 1 if it is not 
missing, and 0 otherwise). Then  𝜃1𝑘 =
1
𝑁(𝑁−1)
∑ ∑ 𝑈1𝑗𝑗′𝑘
𝑁
𝑗≠𝑗′
𝑁
𝑗=1 , which pertains to the probability that a 
random pair of patients is from the same stratum and has a patient in group 1 with larger value for the 𝑘th 
response variable than the other patient in group 2, with tie breaks at probability 0.5; 
𝜃2𝑘 =
1
𝑁(𝑁−1)
∑ ∑ 𝑈2𝑗𝑗′𝑘
𝑁
𝑗≠𝑗′
𝑁
𝑗=1 , which pertains to the probability that a random pair of patients is from 
the same stratum and has non-missing values of the response for endpoint 𝑘 for both patients. In this 
construction, 
 𝑈1𝑗𝑗′𝑘 = 𝐼{(𝑆𝑗 − 𝑆𝑗′) = 0} × [𝐼{(𝑡𝑗 − 𝑡𝑗′)(𝑌𝑗𝑘 − 𝑌𝑗′𝑘)𝑍𝑗𝑘𝑍𝑗′𝑘 > 0} + 0.5 × 𝐼 {(𝑡𝑗 − 𝑡𝑗′)
2
𝑍𝑗𝑘𝑍𝑗′𝑘 >
0} × 𝐼{(𝑌𝑗𝑘 − 𝑌𝑗′𝑘) = 0}] /(𝑛𝑗𝑘 + 𝑛𝑗′𝑘 + 1),  
𝑈2𝑗𝑗′𝑘 = 𝐼{(𝑆𝑗 − 𝑆𝑗′) = 0} × 𝐼 {(𝑡𝑗 − 𝑡𝑗′)
2
𝑍𝑗𝑘𝑍𝑗′𝑘 > 0} /(𝑛𝑗𝑘 + 𝑛𝑗′𝑘 + 1).  
𝐼(𝐴) has the value 1 if the condition 𝐴 is satisfied or the value 0 if otherwise, and 𝑌𝑗𝑘 = 0 when 𝑍𝑗𝑘 = 0 
without loss of generality; 𝑛𝑗𝑘 denote the sample size for the 𝑘th response variable for patients with the 
same stratum and treatment group as the 𝑗th patient. 
A consistent estimator for the covariance matrix for ?̂? is 𝑽?̂? = 𝑫?̂?[𝑫?̂?𝟏
−1, −𝑫?̂?𝟐
−1]𝑉?̅?[𝑫?̂?𝟏
−1, −𝑫?̂?𝟐
−1]𝑫?̂?, 
where𝑭𝑗 = (𝑼𝟏
′ , 𝑼𝟐
′ )′,  ?̅? = (?̂?𝟏′, ?̂?𝟐′)
′, and 𝑉?̅?=
4
𝑁(𝑁−1)
∑ (𝑭𝒋 − ?̅?)(𝑭𝒋 − ?̅?)′
𝑵
𝒋=𝟏 . 
With certain transformations, the above stratified Mann-Whitney estimator for the 𝑘th outcome 
can have an expression that is comparable to the stratified extension of the Wilcoxon rank sum statistics 
of van Elteren [2]. The sum of  𝑈1𝑗𝑗′𝑘 for stratum ℎ produces (𝑛ℎ1𝑘𝑛ℎ2𝑘𝜉ℎ𝑘)/(𝑛ℎ1𝑘 + 𝑛ℎ2𝑘 + 1)𝑁(𝑁 −
1), where 𝜉ℎ𝑘is the Mann-Whitney estimator for the probability that a randomly selected patient in group 
1 has a larger value for the 𝑘th outcome than a randomly selected patient from group 2 in ℎth stratum; and 
sum of 𝑈2𝑗𝑗′𝑘 for the same stratum has the expression (𝑛ℎ1𝑘𝑛ℎ2𝑘)/(𝑛ℎ1𝑘 + 𝑛ℎ2𝑘 + 1)𝑁(𝑁 − 1) and so 
𝜉𝑘 = (∑ 𝑤ℎ𝑘𝜉ℎ𝑘
𝑞
ℎ=1 / ∑ 𝑤ℎ𝑘
𝑞
ℎ=1 ) is the stratified Mann-Whitney estimator for the 𝑘th response variable, 
where 𝑤ℎ𝑘 = (𝑛ℎ1𝑘𝑛ℎ2𝑘)/(𝑛ℎ∗𝑘 + 1) and 𝑛ℎ∗𝑘 = (𝑛ℎ1𝑘 + 𝑛ℎ2𝑘).  
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When the sample size is large enough, e.g., 𝑛+𝑖𝑘 ≥ 50, and all 𝑛ℎ𝑖𝑘 ≥ 4, where 𝑛+𝑖𝑘 =
∑ 𝑛ℎ𝑖𝑘
𝑞
ℎ=1 , ?̂? has an approximately multivariate normal distribution. Thus, the estimate of the overall 
treatment effect is 𝑪′?̂?, and the two-sided 100×(1-2α)% confidence interval for 𝑪′?̂?, with 𝑪′ =
(𝑐1, 𝑐2, … , 𝑐𝑟) is 𝑪′?̂? ± 𝑧𝛼√𝑪′𝑽?̂?𝑪, where 𝑧𝛼 is the 100×(1-α) percentile of the standard normal 
distribution. For the average across all outcomes, 𝑪 = 𝟏𝑟/𝑟. 
A R package called sanon that has all the features for the discussed approaches for the 
implementation of stratified multivariate Mann-Whitney estimators is readily available and 
straightforward to use[6]. 
2.2.2 Randomization Based Nonparametric Covariance Adjustment 
Let 𝑚 = 1, 2, … , 𝑀 represent a set of 𝑀 numerical covariables that have observations (without 
missing data) prior to randomization. Let 𝑥ℎ𝑖𝑚𝑗 be the observed value of the 𝑚th covariable for the 𝑗th 
patient in 𝑖th treatment group of ℎth stratum. Let 𝑔𝑚 = (∑ ?̃?ℎ(?̅?ℎ1𝑚
𝑞
ℎ=1 − ?̅?ℎ2𝑚)/ ∑ ?̃?ℎ
𝑞
ℎ=1 ), with 
?̃?ℎ = 𝑛ℎ1𝑛ℎ2/(𝑛ℎ1 + 𝑛ℎ2), and ?̅?ℎ1𝑚 = ∑ 𝑥ℎ𝑖𝑚𝑗/𝑛ℎ𝑖
𝑛ℎ𝑖
𝑗=1 . Thus 𝑔𝑚 is the estimator from two-way 
analysis of variance for the difference between the stratification adjusted means of the 𝑚th covariable for 
the two groups. Let 𝒇 = (?̂?′, 𝒈′)′, where 𝒈 = (𝑔1, 𝑔2, … , 𝑔𝑚). Since 𝒈 would be expected to be null on 
the basis of randomization of patients to the two groups, randomization-based covariance adjustment of ?̂? 
is possible by fitting the model 𝑷 = [𝑰𝑟 , 𝟎𝑟𝑀]′ to 𝒇 by weighted least squares. The resulting adjusted 
counterpart 𝒃 for ?̂? is = (𝑷′𝑽𝒇
−1𝑷)−1𝑷′𝑽𝒇
−1𝒇 = (?̂? − 𝑽?̂?𝒈𝑽𝒈
−1𝒈) , where 𝑽?̂?𝒈 corresponds to the 
covariance of ?̂? with 𝒈 and 𝑽𝒈 corresponds to the covariance matrix of  𝒈. A consistent estimator for the 
covariance matrix of 𝒃 is 𝑽𝒃 = (𝑷′𝑽𝒇
−1𝑷)−1 = 𝑽?̂? − 𝑽?̂?𝒈𝑽𝒈
−1𝑽?̂?𝒈′. 
2.2.3 Missing Values 
It is common for clinical trials to have missing values for outcomes. Excluding the patients from 
the analysis because of missing values could potentially induce biased results and or reduce power. For 
missing response variables, several approaches have been explored in the applications of multivariate 
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Mann-Whitney estimators [1, 6] assuming MCAR or other paradigms. Besides the approach presented in 
Section 2.1, which manages missing values as missing and assumes MCAR, more settings are available in 
the sanon package. One method manages missing values as tied with all other values in the same stratum 
(in recognition that missing values cannot be classified as better or worse than observed values). Other 
specifications are the last observation carried forward (LOCF) based on the kernels of the U-statistic, or 
the observed value of 𝑌, or the complete cases analyses, in which patients with missing values are 
removed (and MCAR is assumed). 
In addition, multiple imputations can have application when the assumption of MCAR is 
questionable, with missing at random (MAR) being more reasonable. Specifically, assuming multivariate 
normal distributions, data are imputed through PROC MI with Markov chain Monte Carlo (MCMC) 
using SAS, with all the available response variables and covariates included in the imputation model, and 
𝐿 datasets are generated during this step.  SAS version 9.3 is used for the multiple imputations. 
Mann-Whitney estimators 𝝃?̂?, and covariance structure for Mann-Whitney estimators 𝑾?̂? are then 
computed for each of the imputed data sets using the R package sanon. Combining information from each 
of the imputations, one will have ?̅? =
1
𝐿
∑ 𝝃?̂?
𝐿
𝑙=1  and 𝑽?̅? = ?̅̅̅? + (
1
𝐿+1
) 𝑩 as the combined Mann-Whitney 
estimators and their estimated covariance structure, where  ?̅̅̅? =
1
𝐿
∑ 𝑾?̂?
𝐿
𝑙=1  and 𝑩 =
1
𝐿−1
∑ (𝝃?̂? −
𝐿
𝑙=1
?̅?)(𝝃?̂? − ?̅?)
𝑇. Thus, the 95% confidence interval of 𝑪′?̅? can be calculated as 𝑪′?̅? ± 1.96 × √𝑪′𝑽?̅?𝑪. Such 
methods are also applicable to the randomization-based covariance adjusted estimator 𝒃. 
2.2.4 Global Test 
O’Brien [7] proposed a construction of a class of multivariate test statistics for multiple 
endpoints. For general specification of such test statistics when there are no missing data for any 
endpoint, let 𝑌𝑖𝑢𝑘 denote the observed value of the 𝑘th endpoint for the 𝑢th subject for the 𝑖th treatment 
group. Let 𝒀𝑖𝑢 = (𝑌𝑖𝑢1, … , 𝑌𝑖𝑢𝑟)
′, and let ?̅?𝑖 = (∑ 𝒀𝑖𝑢 𝑛𝑖⁄
𝑛𝑖
𝑢=1 ). Under the global null hypothesis 𝐻0 of no 
differences between treatments (in the sense that all patients would have the same values for all endpoints 
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regardless of the randomly assigned treatments), 𝒅 = (?̅?1 − ?̅?2) would have its expected value as 
𝜺(𝒅|𝐻0) = 0, and its known covariance matrix as 
𝑉𝑎𝑟(𝒅|𝐻0) = 𝑽𝒅,0 =
𝑁
𝑛1𝑛2(𝑁 − 1)
∑ ∑(𝒀𝑖𝑢 − ?̅?)(𝒀𝑖𝑢 − ?̅?)
′
𝑛𝑖
𝑢=1
2
𝑖=1
, 
where 𝑁 = (𝑛1 + 𝑛2) and ?̅? = (𝑛1?̅?1 + 𝑛2?̅?2) 𝑁⁄ . Accordingly, 𝒁 = 𝑫
−1𝒅 where 
𝑫 = 𝐷𝑖𝑎𝑔(√𝑣10, … , √𝑣𝑟0) for which the 𝑣𝑘0 are the diagonal elements of 𝑽𝒅,0 has 𝜀(𝒁|𝐻0) = 0 and 
𝑽𝒂𝒓(𝒁|𝐻0) = 𝑫
−1𝑽𝒅,0𝑫
−1 = 𝑽𝒁,0. In this regard, 𝒁 is the vector of standardized differences between 
treatments for the 𝑟 endpoints. For 𝒁, the ordinary least squares test statistic (with equal weights for the 𝑟 
endpoints) is 𝑇𝑂𝐿𝑆 = (𝟏𝑟
′ 𝒁) (𝟏𝑟
′ 𝑽𝒁,0𝟏𝑟)⁄
0.5
 where 𝟏𝑟 is the (𝑟 × 1) vector of 1’s. When the sample sizes 
𝑛1 and 𝑛2 are sufficiently large,  𝑇𝑂𝐿𝑆 has an approximately normal distribution with expected value 0 
and variance 1. Otherwise 𝑇𝑂𝐿𝑆 can have (essentially) exact assessment through enumeration (or 
simulation) of its randomization distribution (with respect to the 𝑁! 𝑛1! 𝑛2!⁄  possible assignments of the 𝑁 
patients to the two groups). A usual version of 𝑇𝑂𝐿𝑆 pertains to the {𝑌𝑖𝑢𝑘} as ranks of the 𝑁 patients for the 
𝑟 endpoints. An alternative test statistic to 𝑇𝑂𝐿𝑆 is the weighted least squares criterion 𝑇𝑊𝐿𝑆 =
(𝟏𝑟
′ 𝑽𝒁,0
−𝟏 𝒁) (𝟏𝑟
′ 𝑽𝒁,0
−𝟏 𝟏𝒓)⁄
0.5
; and it can have better power than 𝑇𝑂𝐿𝑆 when homogeneity applies to 𝒁 in the 
sense that 𝑄 = (𝒁 − 𝑔0𝟏𝑟)
′𝑽𝒁,0
−1 (𝒁 − 𝑔0𝟏𝑟), with 𝑔0 = (𝟏
′𝑽𝒁,0
−1 𝒁) (𝟏′𝑽𝒁,0
−1 𝟏)⁄  is compatible with the chi-
square distribution with (𝑟 − 1) degrees of freedom (d.f.).  
A generalization of O’Brien’s global test with respect to 𝑇𝑂𝐿𝑆 and 𝑇𝑊𝐿𝑆 can have application to a 
multivariate set of 𝑟 estimates ?̂? for multiple comparisons between two treatments with stratification 
adjustment. For example, ?̂? can be a set of Mann-Whitney estimators for a set of ordinal response 
variables. In this paradigm, when the underlying sample sizes are sufficiently large for ?̂? to have an 
approximately multivariate normal distribution with asymptotic expected value 𝜺𝐴(?̂?) = 𝝃 and an 
essentially known covariance matrix 𝑽𝝃 through a consistent estimator 𝑽?̂?, then 
𝑇𝑂𝐿𝑆 = [𝟏𝑟
′ (?̂? − 0.5𝟏𝑟)] (𝟏𝑟
′ 𝑽?̂?𝟏𝑟)
0.5
⁄  has an approximately normal distribution with expected value 0 
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and variance 1 under the global null hypothesis 𝐻0: 𝝃 = 0.5𝟏𝑟. Similar considerations apply to 𝑇𝑊𝐿𝑆 =
[𝟏𝑟
′ 𝑽?̂?
−1(?̂? − 0.5𝟏𝑟)] (𝟏𝑟
′ 𝑽?̂?
−1𝟏𝑟)
0.5
⁄ . Also, if homogeneity applies to 𝝃 in the sense that 𝝃 = 𝟏𝑟𝛿, then 
𝑇𝑂𝐿𝑆 pertains to 𝜺𝐴[𝟏𝑟
′ (?̂? − 0.5𝟏𝑟)] = 𝑟(𝛿 − 0.5) and 𝑇𝑊𝐿𝑆 pertains to (𝟏𝑟
′ 𝑽?̂?
−1𝟏𝑟)(𝛿 − 0.5) =
𝜀𝐴 [𝟏𝑟
′ 𝑽?̂?
−1(?̂? − 0.5𝟏𝑟)].  
2.2.5 Closed Testing Strategy 
A global test with the OLS strategy is performed on the combined endpoints as the OLS average 
of all endpoints.   
𝑇𝑂𝐿𝑆,𝑪 = 𝑪
′(?̂? − 0.5𝟏𝑟)/(𝑪
′𝑽?̂?𝑪)
1/2 ~ 𝑁 (0, 1) 
where ?̂? is the set of combined Mann-Whitney estimators, 𝑽?̂? is the estimated covariance matrix of ?̂?, and 
𝑪 = 𝟏𝑟
′ . 
When the global test is rejected, a closed testing procedure is conducted to identify whether there 
is statistical significance in each of the subsets of endpoints through their OLS combined criterion, or the 
individual endpoints, at a predefined alpha level. As an illustration, if there is a set of 4 endpoints, then 
𝐻1, 𝐻2, 𝐻3, and 𝐻4 represent null hypotheses for the separate endpoints; and the closed family contains 
15 hypotheses representing all possible intersections of 𝐻1, 𝐻2, 𝐻3, and 𝐻4. Each member of the closed 
family can be viewed as a global hypothesis and therefore can be tested using a global test with 
corresponding 𝑪. For example, when testing the hypothesis corresponding to the intersection of the first 
two comparisons, the contrast matrix will be 𝑪 = (1,1,0,0). 
P-values for the hypothesis tests in this closed testing procedure are reported as multiplicity 
adjusted p-values. Specifically, results from a hypothesis and all of the other intersection hypotheses that 
imply this hypothesis are combined and the corresponding adjusted p-values are computed as the largest 
p-value among the p-values for the hypothesis and all the intersection hypotheses that imply it [8]. In this 
sense, if the adjusted p-value for an individual hypothesis test is less than the chosen significance level α, 
then the hypothesis is rejected. 
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2.3 Randomized Clinical Trial for Osteoarthritis (ACTA)  
The illustrative example comes from the first period of a two period crossover clinical trial [9]. 
For this clinical trial, 227 patients were enrolled and randomized to either a test treatment or a control 
group for the management of pain of the hip or knee that was from osteoarthritis. There are three 
associated visits: screen, pre-randomization, and period 1, which are denoted as visit 1, 2, and 3. The 
baseline Kellgren/Lawrence radiographic grade (KL grade) of osteoarthritis (1-4) for patients is managed 
as a stratification factor for illustrative purpose. The two primary outcome measurements were the 
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and the visual analog pain 
scale of the Multidimensional Health Assessment Questionnaire, which is indicated as MDHAQ Pain 
VAS. WOMAC includes three sections of visual analog scales for pain, stiffness and functional status, 
which are indicated as PN-WOMAC, ST-WOMAC and FN-WOMAC. The linear combination of those 
three sub-scales makes the total WOMAC score. Those outcomes are known as strictly ordinal outcomes. 
They have continuous determinations for which an interval scale may not be formally applicable.  
There are no missing values for the outcomes at visit 1, one subject has missing WOMAC at visit 2, and 9 
subjects have missing values for both WOMAC and Pain VAS at visit 3. Also, age was not collected at 
baseline for 5 patients. Based on the observations, the missing pattern is arbitrary. 
2.4 Results 
The analysis adjusts patient age as a covariate, and KL grade as a stratification variable. Since the 
method for covariance adjustment in Section 2.2 requires no missing values for covariates, missing 
covariate age was replaced by the mean age value. Missing values in outcome variables at visit 2 and visit 
3 were managed via the default option from package sanon.  The two outcomes, MDHAQ Pain VAS and 
WOMAC, are analyzed separately or as an average at each of the visits.  
A random baseline imbalance can be observed at visit 2 for WOMAC, with the p-value being 
0.02 (Table 2.1). Through the P matrix in sanon for constraining both visit 1 and 2 response random 
differences to 0 through the nonparametric randomization based ANCOVA, both the separate endpoints 
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and their average show ?̂? > 0.5 and p-value <0.01 at visit 3 (Table 2.2) for more favorable outcome with 
test treatment than placebo.  
Since WOMAC is the linear combination of the three sub-scales that cover three domains of the 
assessment, it would be natural to ask whether the treatment can benefit subjects who suffer from joint 
pain, stiffness, or functional inability and to assess treatment differences for those separate endpoints 
formally with the strong control of FWER. Therefore, with the closed testing strategy, MDHAQ Pain 
VAS and the three components of the WOMAC are illustratively analyzed via stratified Mann-Whitney 
estimators with nonparametric randomization based ANCOVA, adjusting age as covariate, KL grade as 
stratification variable, and P-matrix to constrain the differences between the two randomized groups for 3 
sub-scales of WOMAC and the total MDHAQ Pain VAS from visits 1 and 2 to 0. The global test is 
performed at the one-sided 0.025 level. Because the global test is significant (p < 0.001), 3-way averages 
are tested subsequently. With all 3-way tests significant (p < 0.001), all 2-way averages are tested and 
also are significant (p < 0.002); the individual tests are performed formally at one-sided 𝛼 level 0.025, 
and all individual hypothesis tests are found to be statistically significant in favor of the test treatment 
with multiplicity adjusted one-sided p < 0.006 (Table 2.3).   
In order to examine how this closed testing procedure behaves when the sample size is smaller 
(so that a large effect size may not be seen), the analysis population was restricted to include the subjects 
who had baseline KL grade 3 and 4 (N=128).  As shown in Table 2.4, all three components of the 
WOMAC are significant at the one-sided 0.025 level, while the MDHAQ Pain VAS did not have a 
significant result (although it did have multiplicity adjusted one-sided p = 0.05).  
Six approaches were explored in handling the missing response values for the restricted 
population with baseline KL grade 3 and 4. The sanon package provides a option as “default”, which 
maintains missing values as missing; additional options for “LOCF1” or “LOCF2” represent the “last 
observation carried forward”, which respectively carry forward either the kernels of U-statistics or the 
observed values; “replace” creates ties of the missing value with the values to which it is compared in the 
same stratum; and “remove” is for the complete case analysis. For the multiple imputations, missing age 
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and outcome values were imputed assuming multivariate normal distribution, with all response variables 
and covariates included in the imputation model. A total of 10 datasets were imputed at this step. The 
range of the imputed values is from 0 to 100 to match with the data characteristics. Information from each 
of the imputed datasets is extracted and consolidated to lead to the final results.  The adjusted p-values are 
relatively consistent across the six approaches (Table 2.5).  
2.5 Discussion 
When multiple efficacy endpoints that represent multiple treatment domains are defined in a 
confirmatory clinical trial, the main goal of the trial is first to determine whether the test treatment is 
better than the control. Once the primary goal is met, researchers then would want to know on what 
treatment domains the test treatment is effective. If not well controlled, those multiple comparisons can 
lead to the inflation of type I error, and this can misleadingly suggest significance for findings due to 
chance.  
In the osteoarthritis example, two efficacy endpoints are WOMAC and MDHAQ Pain-VAS, with 
the first pertaining to the standard assessment and monitoring of osteoarthritis, and the second to the 
functional status in activities of daily living. WOMAC is the linear combination of the three subscales 
that evaluate pain, stiffness and functional status of the relevant joints, and so each represents a distinct 
domain of treatment. With the global test, an overall statement that the test treatment is better than the 
control can be achieved. For the next step, within the closed testing framework that ensures the strong 
control of FWER, each of the individual endpoints is evaluated at a predefined significance level.  
The outcome variables WOMAC and MDHAQ Pain-VAS are strictly ordinal measurements. 
They have a narrow range for better outcomes at one end versus a wide range for poorer outcomes at the 
other end, and so the interval scale of the measurement is not strictly applicable to arithmetic operations 
such as addition and subtraction. Therefore, the comparison of such outcome needs to be through ranking, 
specifically, Wilcoxon (or Mann-Whitney) statistics. For a randomized clinical trial with stratified design, 
the van Elteren [2] extension of the Wilcoxon rank sum test is applicable. It can be used regardless of the 
sample sizes within strata. However, when the sample sizes within strata are relatively small (e.g. < 6), 
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the power of the van Elteran test statistic can have limitations. For this reason, adjusting baseline factors 
with randomization based covariance methods needs to be considered carefully [10]. Another limitation 
of the van Elteran test statistic is that it does not provide a corresponding confidence interval. Multivariate 
Mann-Whitney tests only require the sample sizes for each group with each stratum to be at least minimal 
(e.g., ≥ 4) in combination with at least moderate overall sample size for each group (e.g., ≥ 50). In 
addition, with the integration of randomization based nonparametric covariance adjustment, stratified 
Mann-Whitney estimators ?̂? address the probability of a subject from the test treatment group has better 
results compared to a subject from the control group controlling for the baseline characteristics, and a 
95% confidence interval of the point estimates are available. 
Missing values can happen to both baseline and response variables. The package sanon provides 
five approaches in handling missing response variables. However, for the missing values in covariates, 
sanon will exclude those observations from the analysis. For the osteoarthritis trial, five patients had 
missing values for the baseline age. To retain those observations in the analysis, mean age was used to 
replace the missing values in the corresponding analysis. Another concern comes from the MCAR 
assumption. When this assumption does not hold, applying sanon with options that directly handle 
missing values under MCAR assumption may not sufficiently address robustness of results. An 
alternative way to address missing data is to use multiple imputations before calculating multivariate 
Mann-Whitney estimators. This process can be relatively straightforward to achieve with SAS PROC MI, 
and it is also applicable to missing baseline covariates. With the set of 𝐿 imputed datasets, sanon can be 
applied to each of the datasets. The overall multivariate Mann-Whitney estimators and their covariance 
matrix can then be consolidated using the estimators and covariance matrix calculated from each of the 
imputed datasets. 
In summary, the application of the closed testing procedure with multiway averages is effective 
and straightforward to implement. This approach works well with the stratified Mann-Whitney estimators, 
nonparametric randomization based ANCOVA, and multiple imputations.    
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?̂? 
95% CI P-
value 
(one-
sided) 
Lower Upper 
Visit 1 
MDHAQ  0.49 0.41 0.57 0.6181 
WOMAC 0.51 0.43 0.59 0.4165 
Average of MDHAQ and WOMAC 0.50 0.43 0.57 0.5189 
Visit 2 
MDHAQ  0.53 0.46 0.61 0.1934 
WOMAC 0.58 0.50 0.65 0.0218 
Average of MDHAQ and WOMAC 0.56 0.49 0.63 0.0563 
Table 2.1 Mann-Whitney estimators (95% CI) at baseline 
 
 
 
  
?̂? 
95% CI P-
value 
(one-
sided) 
Multiplicity 
Adjusted  
P-value Lower Upper 
Visit 3 
MDHAQ  0.58 0.52 0.64 0.0029 0.0029 
WOMAC 0.61 0.54 0.68 0.0006 0.0006 
Average of MDHAQ and WOMAC 0.60 0.54 0.66 0.0006 0.0006 
Table 2.2 Mann-Whitney estimators (95% CI) at visit 3 
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Contrast Matrix ?̂? 
95% CI P-value 
(one-
sided) 
Multiplicity 
Adjusted  
P-value 
Lower Upper 
4-way 
Average 
(1,1,1,1)/4 0.60 0.54 0.65 0.0003 0.0003 
3-way 
Average 
(1,1,1,0)/3 0.59 0.54 0.65 0.0008 0.0008 
(1,1,0,1)/3 0.60 0.54 0.65 0.0003 0.0003 
(1,0,1,1)/3 0.60 0.55 0.66 0.0001 0.0003 
(0,1,1,1)/3 0.59 0.54 0.65 0.0005 0.0005 
2-way 
Average 
(1,1,0,0)/2 0.59 0.53 0.65 0.0010 0.0010 
(1,0,1,0)/2 0.60 0.54 0.66 0.0005 0.0008 
(1,0,0,1)/2 0.61 0.55 0.67 0.0001 0.0003 
(0,0,1,1)/2 0.60 0.55 0.66 0.0002 0.0005 
(0,1,1,0)/2 0.59 0.53 0.64 0.0019 0.0019 
(0,1,0,1)/2 0.59 0.54 0.65 0.0006 0.0006 
Single 
Endpoint 
(1,0,0,0)- MDHAQ 0.61 0.54 0.68 0.0009 0.0010 
(0,1,0,0)-FN 
WOMAC 
0.58 0.52 0.63 0.0056 0.0056 
(0,0,1,0)-PN 
WOMAC 
0.60 0.53 0.66 0.0011 0.0019 
(0,0,0,1)-ST 
WOMAC 
0.61 0.55 0.67 0.0002 0.0006 
Table 2.3 ACTA trial with closed testing procedure for overall population 
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Contrast Matrix ?̂? 
95% CI P-value 
(one-
sided) 
Multiplicity 
Adjusted  
P-value 
Lower Upper 
4-way 
Average 
(1,1,1,1)/4 0.60 0.53 0.67 0.0019 0.0019 
3-way 
Average 
(1,1,1,0)/3 0.60 0.53 0.67 0.0040 0.0040 
(1,1,0,1)/3 0.60 0.53 0.67 0.0032 0.0032 
(1,0,1,1)/3 0.60 0.53 0.67 0.0021 0.0021 
(0,1,1,1)/3 0.61 0.54 0.68 0.0007 0.0019 
2-way 
Average 
(1,1,0,0)/2 0.59 0.51 0.66 0.0098 0.0098 
(1,0,1,0)/2 0.60 0.52 0.67 0.0069 0.0069 
(1,0,0,1)/2 0.60 0.52 0.67 0.0055 0.0055 
(0,0,1,1)/2 0.62 0.55 0.69 0.0004 0.0021 
(0,1,1,0)/2 0.61 0.54 0.68 0.0015 0.0040 
(0,1,0,1)/2 0.61 0.54 0.68 0.0012 0.0032 
Single 
Endpoint 
(1,0,0,0)- MDHAQ 0.57 0.49 0.66 0.0497 0.0497 
(0,1,0,0)-FN 
WOMAC 
0.60 0.53 0.67 0.0035 0.0098 
(0,0,1,0)-PN 
WOMAC 
0.62 0.54 0.69 0.0011 0.0069 
(0,0,0,1)-ST 
WOMAC 
0.62 0.54 0.69 0.0012 0.0055 
Table 2.4 ACTA trial with closed testing procedure for subpopulation 
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Contrast Matrix Default LOCF1 LOCF2 Replace Remove MI 
4-way 
Average 
(1,1,1,1)/4 0.0019 0.0020 0.0020 0.0015 0.0071 0.0058 
3-way 
Average 
(1,1,1,0)/3 0.0040 0.0042 0.0042 0.0034 0.0143 0.0106 
(1,1,0,1)/3 0.0032 0.0034 0.0034 0.0027 0.0109 0.0088 
(1,0,1,1)/3 0.0021 0.0023 0.0023 0.0018 0.0076 0.0063 
(0,1,1,1)/3 0.0019 0.0020 0.0020 0.0015 0.0071 0.0058 
2-way 
Average 
(1,1,0,0)/2 0.0040 0.0042 0.0042 0.0034 0.0143 0.0106 
(1,0,1,0)/2 0.0040 0.0042 0.0042 0.0034 0.0143 0.0106 
(1,0,0,1)/2 0.0032 0.0034 0.0034 0.0027 0.0109 0.0088 
(0,0,1,1)/2 0.0021 0.0023 0.0023 0.0018 0.0076 0.0063 
(0,1,1,0)/2 0.0040 0.0042 0.0042 0.0034 0.0143 0.0106 
(0,1,0,1)/2 0.0032 0.0034 0.0034 0.0027 0.0109 0.0088 
Single 
Endpoint 
(1,0,0,0)- 
MDHAQ 
0.0497 0.0525 0.0525 0.0466 0.0955 0.0760 
(0,1,0,0)-FN 
WOMAC 
0.0098 0.0104 0.0104 0.0085 0.0297 0.0218 
(0,0,1,0)-PN 
WOMAC 
0.0069 0.0075 0.0075 0.0061 0.0214 0.0159 
(0,0,0,1)-ST 
WOMAC 
0.0055 0.0059 0.0059 0.0048 0.0153 0.0136 
Table 2.5 Results for missing value handling approaches 
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CHAPTER 3 : MULTIPLE SUBGROUPS WITH MULTIPLE ENDPOINTS  
-- an innovative approach for complex multiplicity issues 
3.1 Introduction 
Clinical trials usually enroll a relatively heterogeneous population that represents various 
demographic and medical backgrounds of patients at baseline, so that their results can be generalizable to 
at least one or more subgroups of patients who need an efficacious treatment. Potential candidates for 
defining subgroups include age, gender, disease severity, medical history, geographic region, etc. When 
the goal of the clinical trial is to make primary inferential assessments for one or more of the pre-specified 
subgroups, issues known as multiplicity must be taken into account in study planning [1, 2]. 
Multiplicity commonly arises in confirmatory clinical trials when the effect of the test treatment 
is evaluated in multiple ways. In addition to the previously noted inferential subgroups, there are more 
forms of multiplicity. For example, the scope of multiplicity also includes multiple efficacy endpoints 
when several aspects of the disease need to be assessed, the use of comparisons of several dose levels of a 
single test treatment to control, to one another, or to one or more doses of one or more active control 
treatments, and multiple interim analyses that examine the data for the initial parts of an ongoing study as 
well as at the end of the study. The main concern for multiplicity is that insufficiently controlled multiple 
assessments lead to multiple opportunities for the findings of a clinical trial to be due to chance. Without 
appropriate control, the trial loses its validity because of the inflation of Type I error. For the 
confirmatory clinical trial, strong control of family-wise (or the experiment-wise) Type I error rate 
(FWER) is typically necessary.  
There are many strategies in managing multiplicity that meet the requirement of strong control of 
Type I error, and they can generally be based on closed testing principles [3]. In this regard, closed testing 
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procedures provide strong control of Type I error for all hypotheses in a specified set of hypotheses 
through strong control of Type I error for all of the intersections among such hypotheses. A widely used 
closed testing method is based on hierarchical (or sequential) assessments for a pre-determined order for 
the hypotheses to be tested according to clinical priorities and/or statistical power. For this method, each 
hypothesis in the pre-determined order is assessed at level alpha (with the intersections of these 
hypotheses being the corresponding hypothesis or previous hypotheses in the order). The steps continue 
to the next successive test in the hierarchy if and only if rejections in all previous steps are observed. The 
formal testing stops at the first step where p > alpha, and all subsequent hypotheses are not rejected 
without formal testing. 
Alternatively, when a pre-determined order for two or more hypotheses is not clearly available, 
an alpha propagation method such as the well-known Bonferroni procedure, can be useful for maintaining 
strong control of Type I error; and it can have reasonable power (e.g., at least 0.80) when at least one 
assessment has much higher power than the others (with this scenario being potentially realistic for 2 to 5 
assessments). For this closed testing method, each of the m individual hypotheses is tested at level α/m, 
where α is the pre-specified family-wise Type I error rate (FWER). This procedure is very straightforward 
to implement, and it simultaneously addresses all intersections that pertain to each hypothesis to which it 
is applied. In addition, closed testing extensions of the Bonferroni procedure, such as the Bonferroni-
Holm method and the Hochberg method are widely used for confirmatory clinical trials. Both of these 
methods are based on the ordering of the p-values from the hypothesis tests from the smallest p-value 𝑝(1) 
to the largest p-value 𝑝(𝑚). Accordingly, the Bonferroni-Holm method begins with testing the hypothesis 
corresponding to the smallest p-value at level α/m. If this hypothesis is rejected via 𝑝(1) < 𝛼/𝑚, then the 
second smallest p-value 𝑝(2)is assessed  at the level 𝛼/(𝑚 − 1). Testing continues at 𝛼/(𝑚 − 2), 
𝛼/(𝑚 − 3), … , 𝛼 until there is either failure to reject a corresponding hypothesis (and thereby all 
subsequent hypotheses) or all hypotheses are rejected. The Hochberg method proceeds from the opposite 
direction. It starts with the largest p-value and tests it at level α. If this hypothesis is rejected via 𝑝(𝑚) <
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𝛼, then all hypotheses are rejected. If 𝑝(𝑚) > 𝛼, testing proceeds to the next largest p-value for 
assessment at (𝛼/2) and then to the successively smaller p-values in the ordering at (𝛼/3),  … , (𝛼/𝑚) 
until the largest m* for which there is rejection via (𝑝(𝑚∗) < 𝛼/(𝑚 − 𝑚 ∗ +1)) where m* ≤ m (in which 
case all subsequently ordered hypotheses with smaller p-values are also rejected; or testing can end with 
no hypotheses being rejected).  Whereas the Bonferroni-Holm method has general applicability, 
Hochberg’s method requires independent tests (or non-negatively correlated tests with an appropriate 
structure [4]). In this regard, Hochberg’s method can provide strong control of Type I error for the one-
sided comparisons between test and control treatments for two non-negatively correlated endpoints for 
both the overall population of all patients and a pre-specified inferential subgroup.  
Closed testing through multi-way averages is another useful approach for managing multiplicity 
for endpoints [5] for one-sided comparisons between test and control treatments, but it has been used less 
for current clinical trial planning. It features a global test that addresses a global null hypothesis 
concerning no differences between treatments for endpoints simultaneously, with the potential for testing 
all possible subsets for combinations of endpoints, including the respective separate endpoints, if certain 
requirements are met. The whole process provides strong control of FWER. This strategy is further 
explained in section 3.3. It also can be noted that the previously described multiple testing strategies can 
be used individually or in combinations, and some examples of such applications will be provided in 
Section 3.3.   
When more than one source of multiplicity needs to be managed simultaneously in a 
confirmatory clinical trial, the situation becomes complex and very challenging [2]. An example of such a 
situation is when the trial is focused on making primary inferences on the overall population and/or some 
pre-specified subgroups, while multiple primary endpoints or key secondary endpoints are examined in 
each of the populations [6]. In this manuscript, we consider strategies for this complex multiplicity 
situation through an innovative application of the closed testing procedure with multi-way averages, and 
we note that it controls the FWER in a strong sense while preserving good power. A relevant example 
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based on a real clinical trial is described in Section 3.2, and the proposed approach is presented in Section 
3.3. Section 3.4 provides details on the power of the proposed approach as well as comparisons to some 
of the more well-known strategies through a simulation study.  
3.2 A Real Case Example 
3.2.1 TRA 2
0
P – TIMI 50 trial 
TRA 2
0
P – TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of 
atherothrombotic ischemic event) was a phase III study in subjects who had evidence or history of 
atherosclerosis involving the coronary, cerebral, or peripheral vascular systems. The test treatment was 
Vorapaxar, a protease-activated receptor-1 (PAR-1) antagonist, which is an anti-platelet agent that is 
designed to decrease the tendency of platelets to clump together to form a blood clot. By decreasing the 
formation of blood clots, it decreases the risk of heart attack and stroke. The objective of the study was to 
evaluate the use of Vorapaxar in secondary prevention of cardiovascular (CV) events [6]. 
The trial was conducted in 26,449 subjects with known atherosclerotic disease stratified to three 
hierarchical populations, CAD (all subjects who had a history of myocardial infarction (MI), regardless of 
history of stroke or PAD (peripheral artery disease)), CVD (subjects with history of ischemic stroke, with 
or without PAD), and PAD, with a ratio of 70:15:15. The primary endpoint was a composite of CV death, 
MI, stroke, and urgent coronary revascularization (UCR). The key secondary endpoint was a composite of 
CV death, MI and stroke[7].  
During the course of the study, Vorapaxar was found to increase the risk of intracranial 
hemorrhage in patients with a history of stroke, mainly based on the results from another study [8] but 
also those from TRA 2
0
P – TIMI 50. The Data Safety Monitoring Board (DSMB) then recommended that 
all subjects in the TRA 2
0
P – TIMI 50 study who had any stroke prior to or post randomization to 
discontinue study treatment. This operational change in the study leads to the subsequent considerations 
for the statistical analysis: testing efficacy in the overall and one or more of the sub-populations for the 
primary endpoint and the key secondary endpoint, and strategies for controlling multiplicity.  
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Another question in this trial was the determination of the order for the primary and key secondary 
endpoints.  The two endpoints are: a composite of CV death, MI, stroke, and urgent coronary 
revascularization (UCR), and a composite of CV death, MI and stroke. Thrombolysis in MI Study Group 
(TIMI) and the sponsor did not agree on which one should be the primary endpoint since they are very 
similar and both are important. TIMI proposed to have the composite CV death, MI and stroke as the 
primary endpoint, and putting the other one as the secondary endpoint [6], while the sponsor preferred to 
have them ordered reversely [7]. Under this situation, it could be helpful to have a statistical analysis 
strategy to test both without specific order and account for the multiplicity adjustment efficiently.  
3.2.2 Alternative statistical planning  
The TRA 2
0
P – TIMI 50 trial contains complex multiplicity issues that come from different 
sources – it has multiple inferential subgroups, with multiple endpoints. The eventual statistical planning 
for this trial evolved so as to test the efficacy in the overall population for the primary endpoint first, and 
then the key secondary endpoint if the hypothesis for the primary endpoint was rejected. When both tests 
were statistically significant, testing moved on to the proposed label population[7], which was the CAD 
stratum excluding subjects with history of stroke and transient ischemic attack (TIA) for safety related 
reasons, for the efficacy tests on the primary endpoint and then the key secondary endpoint. This trial had 
significant results (with two-sided p < 0.01) for both endpoints in both populations (Table 3.1). However, 
it was not clear as to how the decision was made to exclude the population of PAD without formal testing 
of efficacy, although one possibility was that the PAD stratum only included about 15% of the 
participants.   
Vorapaxar was later approved by FDA in May, 2014. The indication for this drug is “Patients 
with History of Myocardial Infarction (MI) or with Peripheral Arterial Disease (PAD)”. People who have 
had a stroke, TIA, or intracranial bleeding are excluded from the treatment population for this drug. 
Interestingly, relative to the approved indication, PAD was not included in the original proposed label 
population. It is of interest for both the sponsor and the patient to maximize the benefit of the study drug 
to the population. Therefore, a pre-specified statistical plan that has formal efficacy tests on all three 
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populations, the overall population, CAD plus PAD population, and CAD population, would have been 
reasonable. 
In addition to the strategy used in the trial, other strategies are possible choices in the sense of 
being quite suitable under this situation and widely used in the confirmatory clinical trials. Those 
approaches either combine the alpha propagation method with the sequential method, or they apply the 
sequential method alone to achieve the goal for the trial. Five potential strategies are outlined as follows: 
a. Hochberg I: Assessing the primary endpoint for each of the three populations -- arranging the 
order of the hypothesis tests according to their p-values so that the largest, the second largest and the 
smallest p-values are assessed at level α,  α/2,  and α/3 respectively. If all are successful, then assess the 
secondary endpoint for each of the three populations with the same criteria. 
b. Hochberg II: Assessing the primary and secondary endpoint in the overall population. If both 
succeed, then move on to the two endpoints in CAD + PAD population. If both succeed also, then move 
on to the CAD population. At each stage, endpoints are assessed at level α for the corresponding 
hypothesis with larger p-value, and α/2 for the smaller p-value if the larger p-value exceeds α. This 
approach is most similar to the analysis plan that evolved for the TRA 2
0
P – TIMI 50 trial. 
c. Hochberg III: The order of the testing is the reverse of the Hochberg II, with CAD population 
first, followed by CAD + PAD population, and then the overall population. The primary and the 
secondary endpoint are assessed as in Hochberg II for each of the populations.  
d. Sequential I: The order of the assessments is: overall population first, CAD + PAD population 
second, and CAD population last, with the primary endpoint being assessed prior to the secondary 
endpoint for each of the populations. Everything is tested at level α. Testing stops at the first p-value > α 
and all the subsequent tests are not rejected without formal testing. 
e. Sequential II: This approach is very similar to Sequential I but with the order of the testing as 
CAD population first, CAD + PAD population second, and overall population last with the primary 
endpoint being assessed prior to the secondary endpoint for each of the populations. 
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Since the results in the Vorapaxar trial are all very significant for all three populations with both 
endpoints, the above five strategies have the same results – all 6 population and endpoint combinations 
are successfully significant (two-sided p < 0.01).  
3.3 Multiple Testing Strategy 
A generalization of the situation in the previous example is a confirmatory clinical trial that is 
designed to have primary inference for the test treatment on either the overall population, or some of the 
pre-specified subpopulations, and has two or more equally important efficacy endpoints. The primary 
objective of the trial is to prove treatment efficacy in at least one of the populations for at least one 
endpoint. The previously mentioned five statistical planning methods (a) – (e) can be very useful when 
the order of hypothesis tests can be specified a priori, but when the pre-specification of the order is 
unclear or the order of the hypothesis tests is not important, the application of those methods may not be 
straightforward and may produce a loss of power for some cases.   
In such a situation, we propose a closed testing strategy that is able to work in a more integrated 
way. It starts with a global hypothesis test that is a carefully selected multivariate statistical test, and then 
it proceeds in a closed testing way only when the global hypothesis is rejected. This strategy has the 
ability to address single endpoints for each of the populations in a framework that controls FWER in a 
strong sense [3].   
3.3.1 Global test 
O’Brien [9] proposed a construction of a class of multivariate test statistics for multiple 
endpoints. For general specification of such test statistics when there is no missing data for any endpoint, 
let 𝑌𝑖𝑢𝑘 denote the observed value of the 𝑘th endpoint, 𝑘 =  1, 2, … , 𝑟, for the 𝑢th subject, 𝑢 = 1, … 𝑛𝑖, 
for the 𝑖th treatment group, 𝑖 = 1, 2. Let 𝒀𝑖𝑢 = (𝑌𝑖𝑢1, … , 𝑌𝑖𝑢𝑟)
′, and let ?̅?𝑖 = (∑ 𝒀𝑖𝑢 𝑛𝑖⁄
𝑛𝑖
𝑢=1 ). Under the 
global null hypothesis 𝐻0 of no differences between treatments (in the sense that all patients would have 
the same values for all endpoints regardless of the randomly assigned treatments), 𝒅 = (?̅?1 − ?̅?2) would 
have its expected value as 𝜺(𝒅|𝐻0) = 0, and its known covariance matrix as 
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𝑉𝑎𝑟(𝒅|𝐻0) = 𝑽𝒅,0 =
𝑁
𝑛1𝑛2(𝑁 − 1)
∑ ∑(𝒀𝑖𝑢 − ?̅?)(𝒀𝑖𝑢 − ?̅?)
′
𝑛𝑖
𝑢=1
2
𝑖=1
, 
where 𝑁 = (𝑛1 + 𝑛2) and ?̅? = (𝑛1?̅?1 + 𝑛2?̅?2) 𝑁⁄ . Accordingly, 𝒁 = 𝑫
−1𝒅 where 
𝑫 = 𝐷𝑖𝑎𝑔(√𝑣10, … , √𝑣𝑟0) for which the 𝑣𝑘0 are the diagonal elements of 𝑽𝒅,0 has 𝜀(𝒁|𝐻0) = 0 and 
𝑽𝒂𝒓(𝒁|𝐻0) = 𝑫
−1𝑽𝒅,0𝑫
−1 = 𝑽𝒁,0. In this regard, 𝒁 is the vector of standardized differences between 
treatments for the 𝑟 endpoints. For 𝒁, the ordinary least squares test statistic (with equal weights for the 𝑟 
endpoints) is 𝑇𝑂𝐿𝑆 = (𝟏𝑟
′ 𝒁) (𝟏𝑟
′ 𝑽𝒁,0𝟏𝑟)⁄
0.5
 where 𝟏𝑟 is the (𝑟 × 1) vector of 1’s. When the sample sizes 
𝑛1 and 𝑛2 are sufficiently large,  𝑇𝑂𝐿𝑆 has an approximately normal distribution with expected value 0 
and variance 1. Otherwise 𝑇𝑂𝐿𝑆 can have (essentially) exact assessment through enumeration (or 
simulation) of its randomization distribution (with respect to the 𝑁! 𝑛1! 𝑛2!⁄  possible assignments of the 𝑁 
patients to the two groups). A usual version of 𝑇𝑂𝐿𝑆 pertains to the {𝑌𝑖𝑢𝑘} as ranks of the 𝑁 patients for the 
𝑟 endpoints. An alternative test statistic to 𝑇𝑂𝐿𝑆 is the weighted least squares criterion 𝑇𝑊𝐿𝑆 =
(𝟏𝑟
′ 𝑽𝒁,0
−𝟏 𝒁) (𝟏𝑟
′ 𝑽𝒁,0
−𝟏 𝟏𝒓)⁄
0.5
; and it can have better power than 𝑇𝑂𝐿𝑆 when homogeneity applies to 𝒁 in the 
sense that 𝑄 = (𝒁 − 𝑔0𝟏𝑟)
′𝑽𝒁,0
−1 (𝒁 − 𝑔0𝟏𝑟), with 𝑔0 = (𝟏
′𝑽𝒁,0
−1 𝒁) (𝟏′𝑽𝒁,0
−1 𝟏)⁄  is not contrary to the chi-
square distribution with (𝑟 − 1) degrees of freedom (d.f.). 
3.3.2 Extension of O’Brien’s global test 
More generally, both 𝑇𝑂𝐿𝑆 and 𝑇𝑊𝐿𝑆 are applicable to a multivariate set of 𝑟 estimates ?̂? for 
multiple comparisons between two treatments for comparable multiple endpoints for one or more 
populations. For example, ?̂? can be a set of estimates of log odds ratios for a set of dichotomous 
endpoints or a set of log hazard ratios for a set of time to event endpoints. In this paradigm, when the 
underlying sample sizes are sufficiently large for ?̂? to have an approximately multivariate normal 
distribution with asymptotic expected value 𝜺𝐴(?̂?) = 𝜷 and an essentially known covariance matrix 𝑽𝜷 
through a consistent estimator 𝑽?̂?, then 𝑇𝑂𝐿𝑆 = (𝟏𝑟
′ ?̂?) (𝟏𝑟
′ 𝑽?̂?𝟏𝑟)
0.5
⁄  has an approximately normal 
distribution with expected value 0 and variance 1 under the global null hypothesis 𝐻0: 𝜷 = 𝟎. Similar 
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considerations apply to 𝑇𝑊𝐿𝑆 = (𝟏𝑟
′ 𝑽?̂?
−1?̂?) (𝟏𝑟
′ 𝑽?̂?
−1𝟏𝑟)
0.5
⁄ . Also, if homogeneity applies to 𝜷 in the sense 
that 𝜷 = 𝟏𝑟𝛿, then 𝑇𝑂𝐿𝑆 pertains to 𝜺𝐴(𝟏𝑟
′ ?̂?) = 𝑟𝛿 and 𝑇𝑊𝐿𝑆 pertains to (𝟏𝑟
′ 𝑽?̂?
−1𝟏𝑟) 𝛿 = 𝜀𝐴 (𝟏𝑟
′ 𝑽?̂?
−1?̂?).  
3.3.3 Closed testing procedure 
A closed testing procedure was proposed to identify the significant individual endpoints in 
conjunction with the use of the global test for multiple endpoints in sections 3.3.1 and 3.3.2, if statistical 
significance in the global test is achieved [5]. The procedure is described as follows: 
The system of hypotheses is closed under intersection H = {Ho
I ≡ ⋂ Ho
k
k∈I : I ⊂ {1 … , r}}. It contains all 
marginal hypotheses of the 𝑟 separate endpoints. With this procedure, first, all 𝑟 hypotheses are included 
in a global test of hypothesis at level α (since it corresponds to the intersection of all marginal endpoints 
hypotheses). If this global test rejects the global null hypothesis, then all the hypotheses for the subsets for 
(𝑟 − 1) endpoints are tested using the same type of global test at level α. Next, the tests for all the subsets 
of (𝑟 − 2) endpoints proceed if and only if every hypothesis containing that subset has already been 
rejected. In other words, a hypothesis is rejected if all higher-dimensional marginal hypotheses containing 
this hypothesis are also rejected.  For this procedure, every decision that leads to rejection of a hypothesis 
Ho
I  is controlled by α (figure 3.1). 
To test the hypotheses in this closed testing procedure, results from a hypothesis and all of the 
other intersection hypotheses will need to be combined, and the associated adjusted p-values will need to 
be computed. The adjusted p-value is the largest p-value among the p-values for a hypothesis and all the 
intersection hypotheses that imply it [10, 11].  
3.3.4 Analysis strategy 
In consideration of the operational events that affected study conduct for the example in section 
3.2, and its subsequent impact on the targeted treatment population, and the debate in the determination 
for the hierarchical order of the primary and key secondary endpoints, we propose the following strategies 
to address both issues collectively and prospectively in the study planning for future studies with similar 
objectives:  
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a. Define a set of 6 comparisons that represent the combinations of the three populations and the two 
endpoints of interest as: CAD endpoint 1, CAD endpoint 2, CAD + PAD endpoint 1, CAD + PAD 
endpoint 2, CAD + PAD +CVD endpoint 1, CAD + PAD + CVD endpoint 2, with endpoint 1 and 2 
respectively being analogues to the primary endpoint and the key secondary endpoint in the trial 
design for the example in section 2. The CAD population discussed in this study indicates all CAD 
patients without excluding patients with history of stroke and TIA. Similarly, CAD + PAD and CAD 
+ PAD + CVD populations represent the corresponding populations regardless of patients’ stroke 
and TIA history. 
b. A global test using the OLS strategy will be performed on the OLS average of the 6 comparisons 
defined in the previous step. 
𝑇𝑂𝐿𝑆,𝑪 = (𝑪
′?̂?)/(𝑪′?̂?𝝃𝑪)
1/2 ~ 𝑁 (0, 1) 
where ?̂? is the vector of estimates for the 6 comparisons, 𝑪 = (1, … 1), and ?̂?𝝃 is the estimated 
covariance matrix for the estimates ?̂?.  
c. After the global test is rejected, a closed testing procedure will be conducted to identify whether 
there is statistical significance in each of the subsets of the OLS combined comparisons at a 
predefined alpha level. For example, when testing the hypothesis corresponding to the intersection of 
the first two comparisons, the contrast matrix will be 𝑪 = (1,1,0,0,0,0). 
3.3.5 Covariance matrix estimation 
Since the correlations between endpoints 1 and 2 for the CAD, CVD, and PAD strata were not 
published, a statistical strategy was developed to estimate them. As endpoint 2 is a subset of endpoint 1, 
one would expect to see that endpoint 1 and 2 are highly correlated. Based on the estimate 𝐶𝑜𝑟?̂? =
√
𝑇𝑜𝑡𝑎𝑙 𝑒𝑣𝑒𝑛𝑡𝑠 𝑓𝑜𝑟 𝑒𝑛𝑑𝑝𝑜𝑖𝑛𝑡 2
𝑇𝑜𝑡𝑎𝑙 𝑒𝑣𝑒𝑛𝑡𝑠 𝑓𝑜𝑟 𝑒𝑛𝑑𝑝𝑜𝑖𝑛𝑡 1
, the estimated correlations for the two endpoints for the three strata are 
rounded to 0.8, 0.9, and 0.85. The information provided in Table 1 contains estimates (?̂?) for log hazard 
ratios and their 95% confidence intervals (CI) for the three strata. Thus, variances for each of the 
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estimates can be obtained by solving 𝑣𝑎𝑟(?̂?) = (
log (𝐻𝑅 𝑢𝑝𝑝𝑒𝑟/𝑙𝑜𝑤𝑒𝑟)
1.96×2
)2, where  upper and lower log (𝐻𝑅) 
come from the Cox proportional hazards model for endpoint 1 and 2 in stratum CAD, CVD, PAD 
respectively. The covariance for the two endpoints in each of the strata can be calculated as 
𝑐𝑜𝑣(?̂?𝑎 , ?̂?𝑏) = 𝑐𝑜𝑟?̂? × √𝑣𝑎𝑟(?̂?𝑎) × 𝑣𝑎𝑟(?̂?𝑏), with ?̂?𝑎 and ?̂?𝑏 representing the estimates for endpoint 1 
and 2 from the Cox models for each of the strata. Then the weighted averages are applied to the 
estimation of ?̂? and the covariance matrix 𝑽 ?̂? for the six comparisons: 
?̂? = 𝑨?̂? 
Where 𝑨 = (
𝑰𝟐 𝟎𝟐×𝟐 𝟎𝟐×𝟐
(𝒗𝟏
−𝟏 + 𝒗𝟑
−𝟏)−𝟏𝒗𝟏
−𝟏 𝟎𝟐×𝟐 (𝒗𝟏
−𝟏 + 𝒗𝟑
−𝟏)−𝟏𝒗𝟑
−𝟏
(𝒗𝟏
−𝟏 + 𝒗𝟐
−𝟏 + 𝒗𝟑
−𝟏)−𝟏𝒗𝟏
−𝟏 (𝒗𝟏
−𝟏 + 𝒗𝟐
−𝟏 + 𝒗𝟑
−𝟏)−𝟏𝒗𝟐
−𝟏 (𝒗𝟏
−𝟏 + 𝒗𝟐
−𝟏 + 𝒗𝟑
−𝟏)−𝟏𝒗𝟑
−𝟏
),  
?̂? = (?̂?1, ?̂?2, ?̂?3, ?̂?4, ?̂?5, ?̂?6)
′
, 𝒗𝟏, 𝒗𝟐, and 𝒗𝟑 are the covariance matrices corresponding to the β estimates 
in each of the strata.   
𝑽 ?̂? = 𝒗𝒂𝒓(𝑨?̂?) = 𝑨𝑽 ?̂?𝑨′ 
Where 𝑽 ?̂? = 𝐷𝑖𝑎𝑔 ( 𝒗𝟏, 𝒗𝟐, 𝒗𝟑). 
This estimation process is fairly accurate as the calculated estimates for the six endpoints 
(translated to hazard ratios) and their variances (reflected as the 95% CI) are very close to the values that 
were published (Table 3.2).     
3.3.6 Results for TRA 2
0
P – TIMI 50 trial 
For the proposed multiple testing strategy, a global test was performed on the average of the 
combined 6 comparisons, and statistical significance was achieved. A closed testing procedure with 
multi-way averages was then conducted, and it indicated statistical significance for all six of the proposed 
comparisons that involved all three populations at the one-sided significance level 0.001 (Table 3.3). 
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3.4 Simulation and Results 
3.4.1 Simulation planning 
Assuming the 6 proposed log HRs have a multivariate normal (MVN) distribution with known 
mean values and covariance structure, 10,000 trial results for the 6 endpoints were simulated. Two mean 
vectors were considered in the simulations.  
𝝁𝟏 = log(0.83,0.8,0.86,0.83,0.88,0.87) 
𝝁𝟐 = log(0.825,0.825,0.85,0.85,0.875,0.875) 
𝝁𝟏represents ?̂? that was observed in the trial, and 𝝁𝟐 mimics the situation that the treatment effects on 
endpoint 1 and endpoint 2 in each of the populations are the same.  
Three covariance structures were used in the simulation step. One has the simulations reflect the 
original sample size of the trial with the ratios in stratum CAD, CVD and PVD as 70:15:15, and it is 
indicated as 𝒄𝒐𝒗𝟏(𝒄𝒐𝒗𝟏 = 𝐷𝑖𝑎𝑔 ( 𝒗𝟏, 𝒗𝟐, 𝒗𝟑)). The second has the sample size reduced by 20% for the 
stratum CAD, by 33% for the CVD stratum, and by 50% for the PAD stratum, with this producing about 
an overall 25% reduction in sample size while crudely maintaining the 70:15:15 ratio for the three strata. 
This is indicated as 𝒄𝒐𝒗𝟐 (𝒄𝒐𝒗𝟐 = 𝐷𝑖𝑎𝑔 ( 1.25 × 𝒗𝟏, 1.5 × 𝒗𝟐, 2 × 𝒗𝟑)). The third has the original 
sample size but with the ratios of the sample sizes in the three strata as 1:1:1, and it is indicated as 𝒄𝒐𝒗𝟑 
(𝒄𝒐𝒗𝟑 = 𝐷𝑖𝑎𝑔 ( 2.1 × 𝒗𝟏, 0.45 × 𝒗𝟐, 0.45 × 𝒗𝟑)). 
In the simulation, estimates for each of the comparisons ?̂?𝑠 and their covariance matrix ?̂? 𝝃𝒔 are 
calculated as follows: 
?̂?𝑠 = 𝑨𝝁 
?̂? 𝝃𝒔 = 𝑨𝑽𝝁𝑨′ 
Where 𝝁 is 𝝁𝟏or 𝝁𝟐,  𝑽𝝁 is 𝒄𝒐𝒗𝟏, 𝒄𝒐𝒗𝟐, or 𝒄𝒐𝒗𝟑 
The combinations of the mean vectors 𝝁𝟏, 𝝁𝟐 and covariance structures 𝒄𝒐𝒗𝟏, 𝒄𝒐𝒗𝟐, 𝒄𝒐𝒗𝟑 
provide 6 scenarios in the simulation study, and they are indicated as scenario 1 - 6.  
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For each of the individual simulated trial results, a global test with the OLS average for all 6 
comparisons is performed and a closed testing procedure is conducted only when the global hypothesis is 
rejected. The powers are computed as the proportion of the trials that have significant results based on the 
specified alpha level and for the specified comparisons. 
3.4.2 Results 
The powers of the proposed strategy are generally high for each of the specified comparisons at 
one-sided alpha level 0.025 for all 6 scenarios. For scenario 1 and 2, all powers are above 0.8. Some 
powers are even around 0.9 for endpoint 1, endpoint 2, and endpoint 1 and 2 (where both endpoint 1 and 
endpoint 2 succeed) in the CAD population and the CAD + PAD population, and both the CAD and the 
CAD + PAD population. Since scenarios 3 and 4 represent reduced sample sizes, it is reasonable to 
expect power reduction relative to the other two scenarios. The majority of the powers for these two 
scenarios are between 0.75- 0.85. Scenarios 5 and 6 represent the situation of having the same sample size 
as in the actual trial, but with the ratios of the populations for CAD : PAD : CVD as 1 : 1 : 1. For those 
two scenarios, the powers for endpoint 1, endpoint 2, and endpoint 1 and 2 in the CAD + PAD and the 
overall population are about 0.8 (Figures 3.2).  
Comparisons of the powers between the proposed strategy and the five other approaches (a) – (e) 
in section 3.2.2 were conducted at one-sided alpha level 0.025. The proposed strategy is generally more 
powerful in all of the 6 scenarios with the number of larger powers for the proposed strategy outweighing 
those for the five other strategies for endpoint 1, endpoint 2, endpoint 1 and 2 in the CAD population, the 
CAD + PAD population, overall population, both the CAD and the CAD + PAD population, and all three 
populations together (Figure 3.3).  
The proposed strategy is also as powerful as any of the other approaches for winning both 
endpoint 1 and 2 in all three populations CAD, CAD + PAD, and the overall population for all 6 scenarios 
(Figure 3.3). For the situation of winning both endpoint 1 and 2 in any of the three populations or winning 
any endpoint in any population, the proposed strategy has higher power for more comparisons for all 6 
scenarios. For the scenarios that the proposed strategy has lower powers than the other strategies, those 
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powers are at least 0.8 for the proposed strategy and they are closer to the diagonal lines than most of the 
power points on the other side of the diagonal lines that corresponds to poorer power of other methods 
(Figure 3.3).  
It is observed that the powers are different across the 6 scenarios for each of the strategies (Table 
A 3.1- 3.3), with some strategies having higher powers for scenarios 1 and 2, and other strategies 
performing better for scenarios 5 and 6. Regarding to the powers for endpoint 1, endpoint 2, both 
endpoints, or either endpoint for any of the three populations, the proposed strategy has the least 
differences across the 6 scenarios. In addition, the minimum powers among the 6 scenarios of the 
proposed strategy are generally larger than those of the other strategies, and the maximums of the within 
scenario power difference (the difference between the best power and the power for a method within a 
scenario) for the proposed strategy across the 6 scenarios are consistently smaller comparing to the other 
strategies (Table A 3.3).  
3.5 Discussion 
For the primary inferential assessments of the confirmatory clinical trial, the management of more 
than one source of multiplicity, such as multiple endpoints together with pre-specified multiple subgroups 
as well as the overall population, requires careful attention in the planning for design and analysis. 
Rigorous yet powerful statistical strategies in handling complex multiplicity issues are needed to avoid 
findings by chance, and to assure satisfactory power. In addition, a good strategy also needs to have the 
ability to detect the direction of treatment differences, since almost all of the clinical trials are interested 
in the alternative hypothesis that the test treatment is better than the control.  
The proposed strategy that features a global test followed by a closed testing procedure, which 
tests the subsets of the components through multi-way averages, has clearly shown its effectiveness under 
the framework of controlling FWER at a pre-specified alpha level. Also, it can show the direction of the 
treatment difference through the OLS test. Moreover, O’Brien’s OLS test is very powerful as it takes the 
correlation of the endpoints into account [11].  
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In addition, when a sequential order of hypotheses is hard to determine a priori, or not required, 
the proposed procedure can provide freedom in identifying the winning individual endpoints without pre-
specifying the order of the hypothesis tests. This is an added benefit that the other multiple testing 
approaches mentioned previously do not have. In the example presented previously, five other approaches 
all have certain sequential orders of the hypothesis tests built in them. If those strategies were to be pre-
specified prior to the unmasking of the study, which population and/or endpoint to be tested in the first 
place would not be an easy choice since this decision directly impacts the success of the study. In the 
simulation study, as shown by the two sequential approaches, high power at the beginning of the test 
sequence can be observed, but this effect diminishes rather quickly for the following tests. Thus, when the 
order of the hypothesis tests are pre-specified “correctly”, the powers for some of the hypothesis tests are 
much larger than the same hypothesis tests when the order is specified “incorrectly”, (Table A 3.2, A 3.3). 
The same thing happens for the Hochberg and sequential combined approaches.  
When the sequential order of hypotheses is partially known and may need to be determined a 
priori, the proposed strategy can have application that is similar to Hochberg I, II or III. For example, if 
the order of the hypothesis tests is determined as what has been specified for Hochberg II, the proposed 
strategy can be applied to the testing of the primary and secondary endpoints within each of the 
populations. The p-values will be assessed at level α for both endpoints when the global test is significant. 
When both primary and secondary endpoints have signals, the proposed strategy may have somewhat 
better power than its Hochberg counterparts. Therefore, the proposed strategy not only has the ability to 
handle 6 dimensions of assessments altogether comprehensively, but also has the flexibility of being 
integrated into a sequential assessment framework.  
For the Vorapaxar example, with the CVD population being excluded from the treatment, the 
primary interest is to identify the treatment efficacy in the CAD + PAD population, preferably, or in the 
CAD population, if the efficacy in the larger population is not available, for the two individual endpoints. 
Hochberg I has good powers for endpoint 1, but the powers for the endpoint 2 are much lower. The 
powers of the two endpoints from Hochberg II and sequential I are generally lower compared to the other 
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methods, with powers for scenarios 3 and 4 being very low. Hochberg III and sequential II are very 
powerful for the first two scenarios, but with much lower power for scenarios 5 and 6. The powers for the 
proposed strategy are high for both individual endpoints, and this effect is more consistent across the 6 
scenarios (Table A 3.1, A 3.2).  
For some similar trials, it might be possible that the primary objective for the trial is to identify 
efficacy in either endpoint for any population, or both endpoints for any population. Under this situation, 
the proposed strategy has the largest minimum power across all 6 scenarios comparing to the other 
strategies (Table A 3.3). In addition, for winning either endpoint in any population, the simulation study 
shows the proposed strategy is the most powerful approach considering all 6 scenarios, with the lowest 
power above 0.85, while 30% of the powers from all other approaches combined are less than 0.85. For 
the situations that the proposed strategy has lower power than the other approaches, those powers are all 
above 0.85 for the proposed strategy. In addition, the powers for the proposed strategy across the 6 
scenarios are less different than the other strategies. Therefore, the proposed strategy might be more 
appealing when choosing a multiplicity strategy during the statistical planning stage.  
The application of the OLS average in clinical trials is preferable over the WLS average for the 
global test and the subsequent closed testing procedure [10, 11].  The OLS method simply combines the 
individual test statistics for each of the endpoints with equal weights, while in WLS the endpoints receive 
greater weights if they are less correlated with the other endpoints. In general, WLS is more powerful 
than OLS. But this method is less attractive in clinical applications since it may produce results that are 
uninterpretable. The reason for this is that it is theoretically possible that some endpoints can receive 
negative weights, which may lead to the rejection of the null hypothesis even though the test treatment is 
inferior to the control on some of the corresponding endpoints. 
For the application of the OLS test, it is worth mentioning that the OLS test has better power 
under the assumption of equal effect size across the endpoints. When the spread of the effect sizes 
increases, it loses power. Therefore, during the study planning stage, it is important to evaluate each of 
the endpoints and make decisions on which endpoints are to be included in the global test. For the 
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Vorapaxar study, since the two endpoints are highly correlated with applicable types of events for one 
endpoint nested within those for the other endpoint, it is expected that the effect size of the two endpoints 
should not be very different, or at least if one is significant, the other one will be significant or trending in 
the direction that favors the test treatment. 
This study discusses the multiplicity strategy that applies to three populations, CAD, CAD + 
PAD, and CAD + PAD +CVD, with the patients having history of stroke and TIA being included in the 
analyses. With the consideration that the proposed labeling population being CAD excluding patients 
with stroke and TIA, and the FDA approved population being CAD + PAD without history of stroke and 
TIA, it is possible to extend our proposed strategy to address five populations: all CAD + PAD +CVD 
patients, all CAD + PAD patients, all CAD patients, all CAD + PAD excluding patients with history of 
stroke and TIA, and all CAD patients without history of stroke and TIA. 
As an alternative to Hochberg’s method, the truncated Hommel approach can be another potential 
method to consider for controlling multiplicity [12]. It controls the FWER in the strong sense under the 
same conditions as those necessary for the Hochberg’s method, i.e., when the test statistics are 
independent or positively dependent. We will not discuss this method in detail for this study.      
In summary, the proposed closed multiple testing strategy with multi-way averages is an effective and 
powerful method in controlling FWER for a confirmatory clinical trial. It can handle complex multiplicity 
issues comprehensively. In terms of the minimum power across all 6 of the scenarios, it generally has the 
largest value compared to the other strategies.  
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Tables: 
 
Table 3.1 TRA 2
0
P – TIMI 50 trial results  
Subgroup Endpoint  HR
a
 
95% CI P-value 
(two-
sided)
b
 
Sample Size Number of Events (KM %) 
Lower Upper Vorapaxar Placebo Vorapaxar Placebo 
CAD 
1 0.83 0.76 0.92 <0.001 
8898 8881 
809 (10.5) 956 (12.1) 
2 0.80 0.72 0.89 <0.001 610 (8.1) 750 (9.7) 
CVD 
1 1.02 0.84 1.23 --- 
2435 2448 
217 (12.9) 216 (12.1) 
2 1.03 0.85 1.25 --- 212 (13.0) 208 (11.7) 
PAD 
1 0.95 0.79 1.14 --- 
1892 1895 
233 (12.7) 245 (13.4) 
2 0.94 0.78 1.14 --- 206 (11.3) 218 (11.9) 
CAD+PAD 
1 0.86 0.79 0.93 <0.001 
10790 10776 
1042 (11.0) 1201 (12.5) 
2 0.83 0.76 0.92 <0.001 816 (8.8) 968 (10.2) 
CAD+CVD+PAD 
1 0.88 0.82 0.95 0.001 
13225 13224 
1259 (11.2) 1417 (12.4) 
2 0.87 0.80 0.94 <0.001 1028 (9.3) 1176 (10.5) 
CAD excluding 
stroke and TIA 
1 0.82 0.74 0.90 <0.001 
8458 8439 
719 (8.5) 867 (10.3) 
2 0.78 0.70 0.88 <0.001 352 (6.3) 671 (8.0) 
a
 Hazard ratio is vorapaxar group vs. placebo group 
b
 P-values were calculated based on Cox proportional hazards model 
Published result [6, 7].  
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Table 3.2 Estimated HR and 95% CI based on assumed correlations 
Subgroup Endpoint  HR  
95% CI 
Lower Upper 
CAD 
1 0.83 0.75 0.91 
2 0.80 0.72 0.89 
CAD+PAD 
1 0.85 0.79 0.93 
2 0.83 0.76 0.91 
CAD+CVD+PAD 
1 0.88 0.81 0.95 
2 0.87 0.80 0.94 
 
 
Table 3.3 TRA 2
0
P – TIMI 50 trial results with closed testing strategy  
  
CAD  
Endpoint 1 
CAD  
Endpoint 2 
CAD+PAD 
Endpoint 1 
CAD+PAD 
Endpoint 2 
CAD+PAD+CVD 
Endpoint 1 
CAD+PAD+CVD 
Endpoint 2 
Adjusted p-value  
(one-sided) 
<0.0001 <0.0001 0.0002 <0.0001 0.0005 0.0003 
Alpha (one-sided)       
0.0005 Yes Yes Yes Yes No Yes 
0.001 Yes Yes Yes Yes Yes Yes 
0.0025 Yes Yes Yes Yes Yes Yes 
0.005 Yes Yes Yes Yes Yes Yes 
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Figure 3.1 Closed testing diagram 
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Figure 3.2 Power of closed testing approach for scenario 1-6. 
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Figure 3.3 Power comparisons for closed testing and alternative strategies   
  
 
6
7
 
Additional tables and figures 
Table A 3.1 Power of closed testing strategy for the 6 scenarios. 
  
Scenario 1  
(one-sided alpha level) 
Scenario 2  
(one-sided alpha level) 
0.0005 0.001 0.0025 0.005 0.025 0.0005 0.001 0.0025 0.005 0.025 
CAD Endpoint 1 0.553 0.631 0.736 0.807 0.931 0.565 0.645 0.747 0.814 0.936 
CAD Endpoint 2 0.630 0.702 0.791 0.853 0.952 0.491 0.575 0.689 0.764 0.910 
CAD+PAD Endpoint 1 0.462 0.542 0.653 0.735 0.899 0.506 0.584 0.696 0.772 0.914 
CAD+PAD Endpoint 2 0.556 0.634 0.735 0.805 0.931 0.447 0.531 0.642 0.722 0.887 
CAD+PAD+CVD Endpoint 1 0.399 0.480 0.588 0.676 0.857 0.424 0.505 0.616 0.701 0.877 
CAD+PAD+CVD Endpoint 2 0.385 0.473 0.585 0.672 0.855 0.346 0.430 0.549 0.635 0.832 
CAD Endpoint 1&2 0.523 0.603 0.712 0.789 0.923 0.458 0.543 0.661 0.742 0.900 
CAD+PAD Endpoint 1&2 0.430 0.515 0.627 0.714 0.890 0.405 0.491 0.607 0.692 0.874 
CAD+PAD+CVD Endpoint 1&2 0.313 0.396 0.512 0.606 0.813 0.303 0.384 0.508 0.597 0.811 
CAD and CAD+PAD Endpoint 1 0.450 0.529 0.642 0.727 0.894 0.489 0.567 0.682 0.761 0.909 
CAD and CAD+PAD Endpoint 2 0.540 0.621 0.723 0.796 0.927 0.415 0.499 0.618 0.701 0.877 
CAD and CAD+PAD Endpoint 1&2 0.415 0.499 0.613 0.704 0.883 0.375 0.460 0.580 0.669 0.862 
CAD and CAD+PAD and CAD+PAD+CVD Endpoint 1 0.374 0.454 0.566 0.657 0.847 0.404 0.487 0.600 0.687 0.869 
CAD and CAD+PAD and CAD+PAD+CVD Endpoint 2 0.381 0.469 0.581 0.670 0.853 0.327 0.410 0.530 0.619 0.824 
CAD and CAD+PAD and CAD+PAD+CVD Endpoint 
1&2 0.295 0.376 0.493 0.592 0.805 0.282 0.362 0.485 0.578 0.801 
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Scenario 3  
(one-sided alpha level) 
Scenario 4  
(one-sided alpha level) 
0.0005 0.001 0.0025 0.005 0.025 0.0005 0.001 0.0025 0.005 0.025 
CAD Endpoint 1 0.365 0.445 0.555 0.647 0.840 0.372 0.452 0.564 0.655 0.846 
CAD Endpoint 2 0.417 0.501 0.616 0.703 0.872 0.317 0.392 0.508 0.603 0.809 
CAD+PAD Endpoint 1 0.279 0.352 0.463 0.553 0.778 0.306 0.382 0.499 0.589 0.805 
CAD+PAD Endpoint 2 0.333 0.417 0.538 0.627 0.829 0.263 0.328 0.447 0.542 0.766 
CAD+PAD+CVD Endpoint 1 0.229 0.297 0.404 0.498 0.727 0.242 0.312 0.425 0.519 0.750 
CAD+PAD+CVD Endpoint 2 0.220 0.282 0.389 0.491 0.721 0.199 0.259 0.358 0.457 0.695 
CAD Endpoint 1&2 0.328 0.408 0.522 0.619 0.825 0.285 0.356 0.474 0.571 0.791 
CAD+PAD Endpoint 1&2 0.242 0.316 0.427 0.523 0.759 0.225 0.291 0.405 0.502 0.740 
CAD+PAD+CVD Endpoint 1&2 0.167 0.221 0.320 0.418 0.664 0.165 0.219 0.314 0.408 0.661 
CAD and CAD+PAD Endpoint 1 0.274 0.348 0.458 0.550 0.775 0.300 0.376 0.492 0.582 0.801 
CAD and CAD+PAD Endpoint 2 0.328 0.410 0.531 0.622 0.826 0.253 0.317 0.433 0.528 0.756 
CAD and CAD+PAD Endpoint 1&2 0.236 0.311 0.419 0.518 0.755 0.216 0.281 0.392 0.488 0.729 
CAD and CAD+PAD and CAD+PAD+CVD Endpoint 1 0.213 0.281 0.385 0.479 0.715 0.232 0.301 0.412 0.506 0.742 
CAD and CAD+PAD and CAD+PAD+CVD Endpoint 2 0.220 0.280 0.387 0.488 0.721 0.191 0.250 0.347 0.444 0.687 
CAD and CAD+PAD and CAD+PAD+CVD Endpoint 
1&2 0.157 0.211 0.307 0.405 0.655 0.156 0.209 0.300 0.395 0.651 
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Scenario 5  
(one-sided alpha level) 
Scenario 6  
(one-sided alpha level) 
0.0005 0.001 0.0025 0.005 0.025 0.0005 0.001 0.0025 0.005 0.025 
CAD Endpoint 1 0.217 0.276 0.382 0.470 0.711 0.215 0.276 0.380 0.470 0.710 
CAD Endpoint 2 0.263 0.337 0.447 0.537 0.767 0.172 0.230 0.327 0.416 0.658 
CAD+PAD Endpoint 1 0.284 0.359 0.472 0.568 0.796 0.304 0.379 0.494 0.594 0.811 
CAD+PAD Endpoint 2 0.383 0.469 0.589 0.683 0.864 0.276 0.351 0.473 0.564 0.792 
CAD+PAD+CVD Endpoint 1 0.292 0.370 0.488 0.588 0.809 0.290 0.368 0.486 0.587 0.807 
CAD+PAD+CVD Endpoint 2 0.290 0.372 0.494 0.591 0.814 0.245 0.312 0.428 0.529 0.765 
CAD Endpoint 1&2 0.180 0.237 0.339 0.426 0.675 0.141 0.191 0.283 0.369 0.617 
CAD+PAD Endpoint 1&2 0.269 0.341 0.455 0.554 0.787 0.243 0.316 0.429 0.526 0.766 
CAD+PAD+CVD Endpoint 1&2 0.237 0.307 0.425 0.528 0.771 0.216 0.279 0.392 0.494 0.742 
CAD and CAD+PAD Endpoint 1 0.172 0.230 0.329 0.419 0.678 0.182 0.241 0.342 0.438 0.689 
CAD and CAD+PAD Endpoint 2 0.224 0.297 0.413 0.506 0.748 0.141 0.193 0.290 0.381 0.635 
CAD and CAD+PAD Endpoint 1&2 0.139 0.194 0.290 0.378 0.644 0.114 0.158 0.245 0.334 0.591 
CAD and CAD+PAD and CAD+PAD+CVD Endpoint 1 0.149 0.205 0.303 0.392 0.659 0.159 0.217 0.314 0.411 0.672 
CAD and CAD+PAD and CAD+PAD+CVD Endpoint 2 0.181 0.246 0.359 0.455 0.716 0.122 0.170 0.258 0.350 0.611 
CAD and CAD+PAD and CAD+PAD+CVD Endpoint 
1&2 0.110 0.158 0.250 0.336 0.612 0.096 0.135 0.213 0.300 0.565 
 
  
  
 
7
0
 
Table A 3.2 Power of alternative approaches (one-sided alpha 0.025) 
  
Hochberg I (Scenario) Hochberg II (Scenario) 
1 2 3 4 5 6 1 2 3 4 5 6 
CAD Endpoint 1 0.930 0.948 0.850 0.877 0.704 0.740 0.805 0.806 0.655 0.654 0.631 0.628 
CAD Endpoint 2 0.851 0.848 0.722 0.717 0.627 0.584 0.808 0.802 0.657 0.652 0.665 0.586 
CAD+PAD Endpoint 1 0.897 0.929 0.780 0.834 0.815 0.869 0.809 0.811 0.657 0.659 0.787 0.798 
CAD+PAD Endpoint 2 0.848 0.838 0.709 0.692 0.665 0.671 0.816 0.812 0.667 0.659 0.828 0.802 
CAD+PAD+CVD Endpoint 1 0.865 0.899 0.742 0.788 0.849 0.884 0.853 0.877 0.724 0.752 0.880 0.897 
CAD+PAD+CVD Endpoint 2 0.805 0.803 0.655 0.653 0.641 0.647 0.848 0.830 0.714 0.689 0.870 0.847 
CAD Endpoint 1&2 0.851 0.848 0.722 0.717 0.627 0.584 0.805 0.801 0.655 0.651 0.612 0.565 
CAD+PAD Endpoint 1&2 0.848 0.838 0.709 0.692 0.665 0.671 0.809 0.810 0.657 0.657 0.787 0.791 
CAD+PAD+CVD Endpoint 1&2 0.805 0.803 0.655 0.653 0.641 0.647 0.817 0.815 0.669 0.665 0.842 0.831 
CAD and CAD+PAD Endpoint 1 0.894 0.926 0.779 0.832 0.684 0.726 0.805 0.806 0.655 0.654 0.631 0.628 
CAD and CAD+PAD Endpoint 2 0.845 0.831 0.708 0.688 0.625 0.576 0.808 0.802 0.657 0.652 0.665 0.586 
CAD and CAD+PAD Endpoint 
1&2 
0.845 0.831 0.708 0.688 0.625 0.576 0.805 0.801 0.655 0.651 0.612 0.565 
CAD and CAD+PAD and 
CAD+PAD+CVD Endpoint 1 
0.860 0.896 0.737 0.784 0.675 0.717 0.805 0.806 0.655 0.654 0.631 0.628 
CAD and CAD+PAD and 
CAD+PAD+CVD Endpoint 2 
0.805 0.801 0.655 0.651 0.612 0.565 0.808 0.802 0.657 0.652 0.665 0.586 
CAD and CAD+PAD and 
CAD+PAD+CVD Endpoint 1&2 
0.805 0.801 0.655 0.651 0.612 0.565 0.805 0.801 0.655 0.651 0.612 0.565 
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Hochberg III (Scenario) Sequential I (Scenario) 
1 2 3 4 5 6 1 2 3 4 5 6 
CAD Endpoint 1 0.957 0.959 0.909 0.912 0.707 0.708 0.806 0.808 0.655 0.655 0.647 0.661 
CAD Endpoint 2 0.976 0.935 0.938 0.867 0.760 0.650 0.805 0.801 0.655 0.651 0.612 0.565 
CAD+PAD Endpoint 1 0.909 0.905 0.812 0.809 0.650 0.603 0.809 0.812 0.657 0.660 0.788 0.802 
CAD+PAD Endpoint 2 0.937 0.894 0.854 0.790 0.669 0.601 0.809 0.810 0.657 0.657 0.787 0.791 
CAD+PAD+CVD Endpoint 1 0.838 0.839 0.701 0.698 0.627 0.580 0.875 0.905 0.758 0.799 0.897 0.920 
CAD+PAD+CVD Endpoint 2 0.823 0.810 0.677 0.666 0.619 0.569 0.817 0.815 0.669 0.665 0.842 0.831 
CAD Endpoint 1&2 0.954 0.929 0.900 0.858 0.682 0.622 0.805 0.801 0.655 0.651 0.612 0.565 
CAD+PAD Endpoint 1&2 0.907 0.888 0.806 0.779 0.649 0.596 0.809 0.810 0.657 0.657 0.787 0.791 
CAD+PAD+CVD Endpoint 1&2 0.805 0.801 0.655 0.651 0.612 0.565 0.817 0.815 0.669 0.665 0.842 0.831 
CAD and CAD+PAD Endpoint 1 0.909 0.905 0.812 0.809 0.650 0.603 0.806 0.808 0.655 0.655 0.647 0.661 
CAD and CAD+PAD Endpoint 2 0.937 0.894 0.854 0.790 0.669 0.601 0.805 0.801 0.655 0.651 0.612 0.565 
CAD and CAD+PAD Endpoint 
1&2 
0.907 0.888 0.806 0.779 0.649 0.596 0.805 0.801 0.655 0.651 0.612 0.565 
CAD and CAD+PAD and 
CAD+PAD+CVD Endpoint 1 
0.838 0.839 0.701 0.698 0.627 0.580 0.806 0.808 0.655 0.655 0.647 0.661 
CAD and CAD+PAD and 
CAD+PAD+CVD Endpoint 2 
0.823 0.810 0.677 0.666 0.619 0.569 0.805 0.801 0.655 0.651 0.612 0.565 
CAD and CAD+PAD and 
CAD+PAD+CVD Endpoint 1&2 
0.805 0.801 0.655 0.651 0.612 0.565 0.805 0.801 0.655 0.651 0.612 0.565 
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Sequential II (Scenario) 
      
1 2 3 4 5 6 
      
CAD Endpoint 1 0.961 0.971 0.914 0.929 0.731 0.757 
  
    CAD Endpoint 2 0.954 0.929 0.900 0.858 0.682 0.622 
  
    CAD+PAD Endpoint 1 0.911 0.911 0.818 0.821 0.651 0.607 
  
    CAD+PAD Endpoint 2 0.907 0.888 0.806 0.779 0.649 0.596 
  
    CAD+PAD+CVD Endpoint 1 0.855 0.854 0.726 0.722 0.632 0.585 
  
    CAD+PAD+CVD Endpoint 2 0.805 0.801 0.655 0.651 0.612 0.565 
  
    CAD Endpoint 1&2 0.954 0.929 0.900 0.858 0.682 0.622 
  
    CAD+PAD Endpoint 1&2 0.907 0.888 0.806 0.779 0.649 0.596 
  
    CAD+PAD+CVD Endpoint 1&2 0.805 0.801 0.655 0.651 0.612 0.565 
  
    CAD and CAD+PAD Endpoint 1 0.911 0.911 0.818 0.821 0.651 0.607 
  
    CAD and CAD+PAD Endpoint 2 0.907 0.888 0.806 0.779 0.649 0.596 
  
    CAD and CAD+PAD Endpoint 
1&2 
0.907 0.888 0.806 0.779 0.649 0.596 
  
    CAD and CAD+PAD and 
CAD+PAD+CVD Endpoint 1 
0.855 0.854 0.726 0.722 0.632 0.585 
  
    CAD and CAD+PAD and 
CAD+PAD+CVD Endpoint 2 
0.805 0.801 0.655 0.651 0.612 0.565 
  
    CAD and CAD+PAD and 
CAD+PAD+CVD Endpoint 1&2 
0.805 0.801 0.655 0.651 0.612 0.565 
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Table A 3.3 Power comparisons among strategies (one-sided alpha 0.025) 
  
Scenario 
1 
Scenario 
2 
Scenario 
3 
Scenario 
4 
Scenario 
5 
Scenario 
6 
Minimum 
Power 
Maximum 
Power 
Difference 
Any Population 
Endpoint 1 
Closed testing 0.937 0.943 0.845 0.851 0.856 0.853 0.845 0.078 
Hochberg I 0.934 0.952 0.852 0.881 0.883 0.915 0.852 0.061 
Hochberg II 0.853 0.877 0.724 0.752 0.880 0.897 0.724 0.190 
Hochberg III 0.957 0.959 0.909 0.912 0.707 0.708 0.707 0.212 
Sequential I 0.875 0.905 0.758 0.799 0.897 0.920 0.758 0.156 
Sequential II 0.961 0.971 0.914 0.929 0.731 0.757 0.731 0.165 
Any Population 
Endpoint 2 
Closed testing 0.957 0.921 0.875 0.820 0.888 0.829 0.820 0.063 
Hochberg I 0.855 0.855 0.723 0.721 0.668 0.683 0.668 0.220 
Hochberg II 0.848 0.830 0.714 0.689 0.870 0.847 0.689 0.224 
Hochberg III 0.976 0.935 0.938 0.867 0.760 0.650 0.650 0.197 
Sequential I 0.817 0.815 0.669 0.665 0.842 0.831 0.665 0.269 
Sequential II 0.954 0.929 0.900 0.858 0.682 0.622 0.622 0.225 
Any Population 
Endpoint 1&2 
Closed testing 0.931 0.913 0.830 0.803 0.842 0.813 0.803 0.070 
Hochberg I 0.855 0.855 0.723 0.721 0.668 0.683 0.668 0.177 
Hochberg II 0.817 0.815 0.669 0.665 0.842 0.831 0.665 0.231 
Hochberg III 0.954 0.929 0.900 0.858 0.682 0.622 0.622 0.210 
Sequential I 0.817 0.815 0.669 0.665 0.842 0.831 0.665 0.231 
Sequential II 0.954 0.929 0.900 0.858 0.682 0.622 0.622 0.210 
Any Population 
Any Endpoint 
Closed testing 0.963 0.951 0.890 0.868 0.899 0.869 0.868 0.061 
Hochberg I 0.934 0.952 0.852 0.881 0.883 0.915 0.852 0.095 
Hochberg II 0.885 0.891 0.769 0.776 0.908 0.913 0.769 0.179 
Hochberg III 0.980 0.965 0.947 0.921 0.785 0.736 0.736 0.184 
Sequential I 0.875 0.905 0.758 0.799 0.897 0.920 0.758 0.189 
Sequential II 0.961 0.971 0.914 0.929 0.731 0.757 0.731 0.176 
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CHAPTER 4 : MULTIPLE TREATMENTS, VISITS AND ENDPOINTS 
4.1 Introduction 
Confirmatory clinical trials sometimes are designed to include multiple treatment groups. With 
such a design, it is usually of interest to compare multiple doses of a test treatment with a control group, 
and to compare doses to one another, with the control being a placebo group or a dose of an active 
reference treatment. Often, efficacy data are collected at multiple visits after the treatment begins, with 
the considerations of demonstrating efficacy for long-term use, or immediate/short-term use, or at the visit 
with maximum effect regardless long-term or short-term use. When it is possible to pre-specify a visit that 
ideally will contain the maximum (or long term) treatment effect, efficacy assessed at the pre-specified 
visit is used to make confirmatory inference. However, information on which visit should be chosen is not 
always available a priori for many cases, or it is of sponsor’s interest to claim both short-term and long-
term efficacy.  Thus, efficacy is assessed at two or more visits. In addition, when a single primary 
endpoint is not enough to represent all aspects of the treatment efficacy, multiple endpoints are normally 
involved in the assessment.  
For each of the aforementioned situations, multiplicity occurs when multiple comparisons are 
performed, and thus need control. When three or more sources of multiplicity exist in one confirmatory 
clinical trial simultaneously, the assessment of efficacy is very complicated. Specifically, this can involve 
multiple comparisons between doses of test treatment and control, and /or between doses, for each of the 
endpoints, at pre-specified visits, with the primary goal of the trial to be inferential confirmation for one 
or more of the doses of the test treatment being superior to the control group at one or more visits for at 
least one of the endpoints within that visit, and such inferential confirmation is additionally of interest for 
as many such assessments as applicable. Therefore, an efficient and powerful strategy that evaluates the 
efficacy of the test treatment with strong control of the family wise error rate (FWER) is of interest.  
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In addition, for the clinical trial that has multiple dose groups, it is common to believe that the higher dose 
may be more efficacious than the lower dose. Thus, the prevailing multiplicity adjustment approaches 
tend to place more emphasis on the higher dose through a Hochberg approach applied under a fixed 
sequential testing framework, so that the hypotheses corresponding to the higher dose are tested with 
higher priority.  With such a hierarchy built in the evaluation process, the lower dose is only assessed 
when the higher dose has significant results. This reduces the power for detecting signals in the lower 
dose. However, it might also be true that the higher dose is associated with more safety concerns than the 
lower dose. Therefore, it is important to have an assessment strategy that evaluates the higher dose and 
the lower dose equally. 
Here, we consider a closed testing procedure combined with a sequential testing procedure, and 
an alternative strategy as a closed testing procedure under a parallel gatekeeping framework for the 
previously described complex multiplicity situation. We illustrate those strategies with a realistic example 
and examine the power of the proposed strategies using a simulation study. 
4.2 An Illustrative Example 
4.2.1 Suvorexant Trials 
The Suvorexant development program included 2 phase 3 clinical trials that were designed to 
evaluate the efficacy and safety of suvorexant for the treatment of insomnia.  Suvorexant is a dual orexin 
receptor antagonist (DORA) [1]. It transiently inhibits the effects of wakefulness-promoting orexin 
neurons of the arousal system, thus facilitating the natural transition from wake to sleep.  It is the first of a 
new class of drugs. 
Nonelderly (18-65 years) and elderly (≥65 years) patients, who met the inclusion criteria, were 
enrolled and randomized to placebo, the low dose or the high dose group, with the low dose being 20/15 
mg and the high dose being 40/30 mg (for the nonelderly group, 40 mg was considered as high dose and 
20 mg as low dose; for the elderly group, 30 and 15 mg were considered as high and low dose, 
respectively). Efficacy was assessed using subjective measures with an e-diary completed each morning 
by the patient that recorded sTST (subjective total sleep time in minutes) and sTSO (subjective time to 
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sleep onset in minutes) at week 1, and the end of month 1 and month 3; and also objective measures by 
polysomnography (PSG) that recorded LPS (latency to onset of persistent sleep) and WASO (mean 
wakefulness after persistent sleep onset) at night 1, and the end of month 1 and month 3. The primary 
endpoints for the high dose compared to placebo were changes from baseline at month 1 and 3 for sTST, 
sTSO, LPS, and WASO. The secondary endpoints for the high dose compared to the placebo were 
changes of the same four endpoints that were assessed at week 1 (for the subjective measurements) and 
night 1 (for the objective measurements). These endpoints were also assessed for the low dose compared 
to the placebo as additional secondary endpoints (for trial 1) and as the exploratory endpoints (for trial 2).  
All patients were assessed either with e-diary only (Q-cohort) or PSG and e-diary (PQ-cohort) for both 
trials. Patients were randomized to the high dose, the low dose, and placebo in a 3:2:3 ratio in trial 1, and 
a 1:1:1 ratio (Q-cohort) or a 2:1:2 ratio (PQ-cohort), which leaves the final ratio of the randomized 
subjects in the combined trial as 3:2:3. Detail of study design and assessment can be found in paper 
published by Herring et. al. [1]. 
4.2.2 Suvorexant Trial Statistical Planning  
As the result of having complex multiplicity issues, the statistical planning for this trial evolved in 
the following way to maintain FWER [1]. The positive results were defined as meeting the pre-defined 
two-sided α = 0.05 significance level through results favoring the test treatment, which is equivalent to 
the one-sided 0.025 level. For the two distinct indications, sleep maintenance (sTST and WASO) and 
onset (sTSO and LPS), a Bonferroni approach was used so that each of the indications was evaluated at 
𝛼 2⁄ = 0.025  for the high dose vs. placebo in the primary analysis.  
Within each indication, a fixed sequential testing procedure was used to start the assessments 
with the first set of primary hypotheses (month 1) prior to the next set of primary hypotheses (month 3). 
Specifically, at each time point, a Hochberg approach was used to test both the subjective and the 
objective (e.g. sTST and WASO) endpoints. If both the subjective and the objective outcomes were 
significant for month 1, indicated by the larger one-sided p-value of the two hypotheses less than 0.0125, 
the hypothesis testing proceeded to month 3 for the high dose. If only one endpoint was significant at 
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month 1, testing was stopped at month 1, and no further testing was done for month 3. At month 3, if 
either one of the hypotheses (e.g. sTST and WASO) had a significant result, then the secondary 
hypotheses (Week 1, Night 1) for the high dose vs. placebo were tested using the Hochberg approach at a 
one-sided α = 0.0125 level (although more formally, statistical significance for both endpoints at month 3 
is necessary to proceed to the secondary hypotheses).  
The low dose comparisons to the placebo were evaluated as the secondary hypotheses in trial 1, 
and as the exploratory hypotheses in trial 2. For the multiplicity control in trial 1, if at least one of the 
month 3 primary endpoints was positive for the high dose vs. placebo, a similar approach was taken for 
the low dose vs. placebo comparisons as described previously, with the additional requirement that for a 
particular endpoint, the high dose comparison to placebo must be significant in order to declare the low 
dose comparison to placebo significant (although more formally, statistical significance for both 
endpoints at month 1, month 3, and night 1/week 1 is necessary for the high dose in order to proceed to 
any testing for the secondary hypotheses for the low dose) (Figure A 4.1). 
Following the multiplicity adjustment rules, it was demonstrated that the suvorexant high dose 
was superior to placebo on almost all of the subjective and objective endpoints at all three time points in 
both trials, with LPS at month 3 in trial 2 being the exception. However, the safety analysis suggested 
some concerns associated with the high dose. The low dose was descriptively better than the placebo with 
one-sided p < 0.0125 for the indication of sleep maintenance at all three time points in trial 1. For the 
indication of sleep onset, the low dose was better for LPS at month 1 with one-sided p < 0.0125 but did 
not differ from placebo at any of the other time points, or on sTSO at any time points (relative to one-
sided p > 0.0125).  
Although the efficacy of the low dose with respect to both sleep onset and sleep maintenance was 
not assessed formally in both studies, FDA approved suvorexant in August, 2014 at the lower doses of 10 
mg (studied in Phase 2), 15 mg and 20 mg for both indications on the basis of the totality of the clinical 
data. (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm409950.htm).  
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4.2.3 Alternative Strategies  
In addition to the multiplicity adjustment approach used in the trial, other related strategies that 
are related to this approach and are possible choices in such a situation are listed as follows, with each 
indication evaluated at 𝛼 2⁄ = 0.0125 one-sided. 
A: This strategy is very similar to what was originally planned, with modifications so that FWER 
is controlled more formally. Basically, statistical significance for both primary endpoints at each step is 
necessary to proceed to the subsequent step of the sequential tests.  
B: Within each indication, the step down Bonferroni-Holm approach can be used in the 
evaluation of the high dose vs. placebo for the two primary endpoints at month 1 and month 3. If all 
results for the hypothesis tests are significant, the assessment moves to the comparisons of the high dose 
to the placebo at night 1/week 1, and testing them with the step down Bonferroni-Holm approach. The 
comparisons for the low dose vs. placebo are conducted only when all of the high dose comparisons are 
significant. The testing for the low dose vs. placebo is conducted in the same way as what was specified 
for the high dose vs. placebo.     
C: Within each indication, the night 1/week 1, month 1 and month 3 endpoints for the high dose 
comparisons to the placebo are evaluated with the step down Bonferroni-Holm approach. If all of the 
results for the endpoints are significant, the evaluation moves to the comparisons of the low dose to the 
placebo, with the same method as for the comparisons of the high dose to the placebo. 
Alternative strategies A, B and C place more emphasis on the high dose, like what was originally planned 
in the trial. Only when all of the results for the high dose achieve significance can evaluation proceed to 
the low dose is to be evaluated. Therefore, the power for detecting signals in the low dose group is 
limited. The following strategies emphasize the high dose and the low dose similarly. 
D: Within each indication, the high dose vs. placebo and the low dose vs. placebo for both 
primary endpoints at month 1 are evaluated using the Hochberg approach. If all positive, the hypothesis 
tests evaluate endpoints at month 3 for both doses. If all of their results are significant, then the testing 
similarly proceeds with the night 1/week 1 endpoints for both doses.  
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A parallel gatekeeping approach also has the ability to evaluate the low dose and the high dose 
concurrently. Specifically, within each of the indications, two subsets of hypotheses are formed so that the 
high dose vs. placebo and the low dose vs. placebo can be evaluated in parallel. For each individual 
subset, adjustments for multiplicity are performed so that the assessments are at one-sided 𝛼/8. If 
everything is significant for one subset of the dose comparisons, 𝛼/8 can be allocated to the other subset 
of the dose comparisons, and the evaluation of the other dose can be performed at one-sided 𝛼/4. The 
following strategies PA, PB, and PC are the parallel gatekeeping counterparts of strategy A, B and C 
respectively, with the high dose and the low dose being assessed in parallel, and shifting the allocated 
significance level for one subset to the other subset when the one subset has all of its results significant. 
PA: Within each subset, one for the high dose and one for the low dose, two primary endpoints at 
month 1 are evaluated with the Hochberg approach. If both have significant results, then the two 
endpoints at month 3 are evaluated with the same approach. If both achieve significant results, hypothesis 
testing moves to the two endpoints at night 1/week 1. 
PB: Within each subset of the dose comparisons, the primary endpoints at month 1 and month 3 
are evaluated using the step down Bonferroni-Holm approach. If the results for all of them are significant, 
the hypothesis testing moves to the night 1/week 1 comparisons.  
PC: Within each subset of the dose comparisons, the endpoints at night 1/week 1, month 1 and 
month 3 are evaluated using the step down Bonferroni-Holm approach. 
4.3 Modified Statistical Planning 
4.3.1 Global test 
O’Brien [2] proposed a construction of a class of multivariate test statistics for multiple 
endpoints. For general specification of such test statistics when there is no missing data for any endpoint, 
let 𝑌𝑖𝑢𝑘 denote the observed value of the kth endpoint, where 𝑘 =  1, 2, … , 𝑟, for the uth subject, where 
𝑢 = 1, … 𝑛𝑖, for the ith treatment group, where 𝑖 = 1, 2. Let 𝒀𝒊𝒖 = (𝑌𝑖𝑢1, … , 𝑌𝑖𝑢𝑟)
′, and let ?̅?𝒊 =
(∑ 𝒀𝒊𝒖 𝑛𝑖⁄
𝑛𝑖
𝑢=1 ). Under the global null hypothesis 𝐻0 of no differences between treatments (in the sense 
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that all patients would have the same values for all endpoints regardless of the randomly assigned 
treatments), 𝒅 = (?̅?1 − ?̅?𝟐) would have its expected value as 𝜀(𝒅|𝐻0) = 𝟎, and its known covariance 
matrix as 
𝑉𝑎𝑟(𝒅|𝐻0) = 𝑽𝒅,0 =
𝑁
𝑛1𝑛2(𝑁 − 1)
∑ ∑(𝒀𝒊𝒖 − ?̅?)(𝒀𝒊𝒖 − ?̅?)
′
𝑛𝑖
𝑢=1
2
𝑖=1
, 
where 𝑁 = (𝑛1 + 𝑛2) and ?̅? = (𝑛1?̅?𝟏 + 𝑛2?̅?𝟐) 𝑁⁄ . Accordingly, 𝒁 = 𝑫
−𝟏𝒅 where 
𝑫 = 𝐷𝑖𝑎𝑔(√𝑣10, … , √𝑣𝑟0) for which the 𝑣𝑘0 are the diagonal elements of 𝑽𝒅,𝟎 has 𝜀(𝒁|𝐻0) = 𝟎 and 
𝑉𝑎𝑟(𝒁|𝐻0) = 𝑫
−𝟏𝑽𝒅,0𝑫
−𝟏 = 𝑽𝒁,0. In this regard, 𝒁 is the vector of standardized differences between 
treatments for the 𝑟 endpoints. For 𝑍, the ordinary least squares test statistic (with equal weights for the 𝑟 
endpoints) is 𝑇𝑂𝐿𝑆 = (𝟏𝒓
′ 𝒁) (𝟏𝒓
′ 𝑽𝒁,0𝟏𝒓)⁄
0.5
 where 𝟏𝒓 is the (r × 1) vector of 1’s. When the sample sizes 
n1 and n2 are sufficiently large,  𝑇𝑂𝐿𝑆 has an approximately normal distribution with expected value 0 and 
variance 1. Otherwise 𝑇𝑂𝐿𝑆 can have (essentially) exact assessment through enumeration (or simulation) 
of its randomization distribution (with respect to the 𝑁! 𝑛1! 𝑛2!⁄  possible assignments of the 𝑁 patients to 
the two groups). A usual version of 𝑇𝑂𝐿𝑆 pertains to the {𝑌𝑖𝑢𝑘} as ranks of the 𝑁 patients for the 𝑟 
endpoints. An alternative test statistic to 𝑇𝑂𝐿𝑆 is the weighted least squares criterion 
𝑇𝑊𝐿𝑆 = (𝟏𝒓
′ 𝑽𝒁,0
−𝟏 𝒁) (𝟏𝒓
′ 𝑽𝒁,0
−𝟏 𝟏𝒓)⁄
0.5
; and it can have better power than 𝑇𝑂𝐿𝑆 when homogeneity applies to 
𝑍 in the sense that 𝑄 = (𝒁 − 𝑔0𝟏𝒓)
′𝑽𝒁,0
−𝟏 (𝒁 − 𝑔0𝟏𝒓), with 𝑔0 = (𝟏
′𝑽𝒁,0
−𝟏 𝒁) (𝟏′𝑽𝒁,0
−𝟏 𝟏)⁄  is not contrary to 
the chi-square distribution with (𝑟 − 1) degrees of freedom (d.f.). 
4.3.2 Extension of O’Brien’s global test 
More generally, both 𝑇𝑂𝐿𝑆 and 𝑇𝑊𝐿𝑆 are applicable to a multivariate set of 𝑟 estimates ?̂? for 
multiple comparisons between two treatments for multiple endpoints for one or more populations. For 
example, ?̂? can be a set of estimates of mean differences between the test treatment and control group for 
a set of continuous endpoints. In this paradigm, when the underlying sample sizes are sufficiently large 
for ?̂? to have an approximately multivariate normal distribution with asymptotic expected value 𝜀𝐴(?̂?) =
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𝜷 and an essentially known covariance matrix 𝑽𝜷 through a consistent estimator 𝑽?̂?, then 𝑇𝑂𝐿𝑆 =
(𝟏𝒓
′ ?̂?) (𝟏𝒓
′ 𝑽?̂?𝟏𝒓)
0.5
⁄  has an approximately normal distribution with expected value 0 and variance 1 
under the global null hypothesis 𝐻0: 𝛽 = 0. Similar considerations apply to 
𝑇𝑊𝐿𝑆 = (𝟏𝒓
′ 𝑽?̂?
−𝟏?̂?) (𝟏𝒓
′ 𝑽?̂?
−𝟏𝟏𝒓)
0.5
⁄ . Also, if homogeneity applies to β in the sense that 𝛽 = 𝟏𝑟𝛿, then 
𝑇𝑂𝐿𝑆 pertains to 𝜀𝐴(𝟏𝒓
′ ?̂?) = 𝑟𝛿 and 𝑇𝑊𝐿𝑆 pertains to (𝟏𝒓
′ 𝑽?̂?
−𝟏𝟏𝒓) 𝛿 = 𝜀𝐴 (𝟏𝒓
′ 𝑽?̂?
−𝟏?̂?). 
4.3.3 Closed testing procedure 
A global test with the OLS strategy is performed on the combined endpoints as the OLS average 
of all endpoints.   
𝑇𝑂𝐿𝑆 = (𝑪
′?̂?)/(𝑪′?̂?𝜷𝑪)
𝟏/𝟐 ~ 𝑁 (0, 1) 
where ?̂? is the vector of estimates for the comparisons, 𝑽?̂? is the estimated covariance matrix of ?̂?, and 
𝑪 = 𝟏𝑟
′ . 
When the global test is rejected, a closed testing procedure is conducted to identify whether there 
is statistical significance in each of the subsets of endpoints through their OLS combined criterion, or the 
individual endpoints, at a predefined alpha level [3]. As an illustration, if there is a set of 4 endpoints, 𝐻1, 
𝐻2, 𝐻3, and 𝐻4 represent null hypotheses for the separate endpoints; and the closed family contains 15 
hypotheses representing all possible intersections of 𝐻1, 𝐻2, 𝐻3, and 𝐻4. Each member of the closed 
family can be viewed as a global hypothesis and therefore can be tested using a global test with 
corresponding 𝑪. For example, when testing the hypothesis corresponding to the intersection of the first 
two comparisons, the contrast matrix will be 𝑪 = (1,1,0,0). 
Alternatively, the global test can be achieved through a multi-degree of freedom test: 
𝑄 = ?̂?′𝑨′(𝑨?̂?𝜷𝑨
′)−𝟏𝑨?̂?  
where 𝑨 is a 𝑟 × 𝑟 matrix with value 1 in the matrix for the corresponding endpoints to be evaluated and 0 
elsewhere, where 𝑟 is the number of endpoints, and 𝑄 has the Chi-squared distribution with degree of 
freedom 𝑟. For the subsequent closed testing, 𝑨 can be a subset of rows of 𝐼𝑟. 
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P-values for the hypothesis tests in this closed testing procedure are reported as multiplicity 
adjusted p-values. Specifically, results from a hypothesis and all of the other intersection hypotheses that 
imply this hypothesis are combined and the corresponding adjusted p-values are computed as the largest 
p-value among the p-values for the hypothesis and all the intersection hypotheses that imply it [4]. In this 
sense, if the adjusted p-value for an individual hypothesis test is less than the chosen significance level α, 
then the hypothesis is rejected. 
4.3.4 Multiplicity strategy 
For the confirmatory clinical trials that are similar to the suvorexant trial in design, the primary 
goal is to provide confirmation for the treatment efficacy for both endpoints for at least one dose at any of 
the visits, and the secondary goal is to achieve confirmation for as many comparisons as possible. 
Therefore, the multiplicity strategy in place needs to reflect the goals of the trial. In the suvorexant trial, 
the low dose was only evaluated if the high dose achieved statistical significance. It might be generally 
true that the high dose is more efficacious than the low dose. However, it might be also true that the high 
dose is associated with more safety concerns. Also, in this trial, month 3 hypotheses were evaluated only 
when both hypothesis tests were significant at month 1. When it is hard to determine which of the visits 
carries the larger effect size a priori, using the fixed sequential testing may be less powerful.     
Considering all the issues noted here collectively, we propose the following analysis plans that 
combine a closed testing procedure with sequential testing, and alternatively, a closed testing procedure 
under a parallel gatekeeping framework. 
1. Five strategies that combine the closed testing procedure with sequential testing are discussed in 
terms of prioritizing the evaluations for the high dose, or both high dose and low dose, at month 
1, or at both month 1 and month 3.  
CT1, CT2, and CT3 are the counterparts of the strategies A, B, and C. CT4 has the same structure 
and the sequential order for the evaluation corresponding to the strategy D. It is also similar to the 
strategy PA. CT5 is similar to the strategy PB. In all of those analyses, the closed testing 
procedure replaces the corresponding Hochberg or the step down Bonferroni-Holm approach 
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where applicable. In order for the analysis to proceed to the next comparisons in sequence, all 
assessments in the previous step need to have significant results (Figure 4.1).    
2. Three strategies that combine the closed testing procedure with a parallel gatekeeping framework 
are developed. CTPA, CTPB, and CTPC are the counterparts for the strategies PA, PB, and PC, 
with the closed testing procedure replacing the corresponding Hochberg or the step down 
Bonferroni-Holm approach. If all assessments for a dose are positive, its significance level can be 
allocated to the assessments for the other dose (Figure 4.2). 
The global test is performed sequentially as specified in the strategy CT1-CT5, and CTPA, CTPB, 
and CTPC. Conditional on the rejection of the global test, a closed testing procedure is then conducted to 
identify whether there is statistical significance in each of the subsets of the comparisons at a 
predetermined one-sided significance level.  
4.4 Results of the Combined Suvrorexant Studies 
Since trial 1 and 2 are identical in design for efficacy evaluation, and the sample sizes for the low 
dose group are 30-40% less compared to the other two arms by design, those two trials are combined 
together for the subsequent analyses so that the power of detecting the signals in the low dose group 
increases. In addition, for simplicity, only endpoints from one indication, sleep maintenance, are used in 
the analyses. The analyses are evaluated at one-sided 𝛼 = 0.001. 
For the following 12 comparisons, sTST and WASO, at month 1, month 3, and week 1/night 1, 
for the high dose and the low dose, all multiplicity adjusted p-values are extremely small (<0.0001), and 
so the combined study has significant results for each of the comparisons from all strategies A-D, PA, PB, 
PC, CT1-CT5, CTPA, CTPB, and CTPC. 
4.5 Simulation Study  
4.5.1 Simulation Parameters 
Assuming the 12 comparisons (mean differences between test treatment and placebo for the two 
outcomes for two doses at 3 time points) have a multivariate normal (MVN) distribution with known 
mean values and covariance structure, 10,000 trial results for the 12 comparisons are simulated under the 
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alternative specifications. The following five vectors are planned for the simulation: the mean vector for 
the specifications includes the set of estimates observed in the suvorexant combined trials (Table A 4.1a), 
a vector with the treatment effect reduced by 20% for all estimates, a vector with the treatment effect 
reduced by 50% for the estimates at visit 1 (represents week 1/night 1 in the real study) and reduced by 
20% for the estimates at visit 2 or 3 (represents month 1 or 3 in the real study), a vector with the treatment 
effects reduced by 20% for the low dose and reduced by 50% for the high dose, and the null vector. 
Five covariance structures are planned for the simulation: the observed covariance structure for the set of 
12 comparisons (Table A 4.1b), the covariance structure that corresponds to the sample size reduced 
roughly by 15% (by multiplying the observed covariance matrix by 1.2), reduced by 30% (by multiplying 
the observed covariance matrix by 1.4), the covariance structure that corresponds to the ratio of the three 
arms as 1:1:1 through effectively  decreasing the sample size of the high dose and the placebo group to 
2/3 of their original sample sizes,  and the covariance structure that corresponds to the ratio of the three 
arms as 1:2:2 through effectively  decreasing the sample size of the high dose to 1/3 and the placebo 
group to 2/3 of their original sample sizes.  The covariance matrix for the 18 endpoints (with respect to 2 
endpoints at 3 visits by 3 treatment groups, which corresponds to an 18 by 18 matrix) was used for 
adjusting the ratio of the three arms. Specifically, the 18 by 18 matrix was pre- and post- multiplied by a 
diagonal matrix, with the entry of the diagonal matrix being the Kronecker product of the vector 
(𝑑1, 𝑑2, 𝑑3) and 𝟏6
′ , with (𝑑1, 𝑑2, 𝑑3) being (√1.5, 1, √1.5) for the ratio of placebo, low dose, and high 
dose as 1:1:1 for, and (√3, 1, √1.5) for the ratio of the three arms as 1:2:2. With the modified 18 by 18 
covariance matrix, a 12 by 12 covariance matrix that accounts for the 12 comparisons (corresponds to 
high vs. placebo and low vs. placebo for 2 endpoints at 3 visits) was then calculated and used in the 
simulation. The combinations of the mean vectors and the covariance structures will provide 21 scenarios 
in the simulation study (Table 4.1).  
For each of the simulated trial results, the proposed closed testing strategies, CT1-CT5, CTPA, 
CTPB and CTPC, and the alternative strategies A-D, PA, PB and PC are applied. The FWER is specified 
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as one-sided 𝛼 = 0.025. The powers are computed as the proportion of the trials that have significant 
results based on the multiplicity adjustment rules. Powers are compared across the strategies. 
4.5.2 Simulation Results 
Comparison of the strategies are made between A vs. CT1, B vs. CT2, C vs. CT3, D vs. CT4, A 
vs. CT4, B vs. CT5, A vs. CTPA, B vs. CTPB, C vs. CTPC, D vs. CTPA, PA vs. CTPA, PB vs. CTPB, 
and PC vs. CTPC in terms of power and the mean number of positive evaluations for all of the 21 
simulated scenarios. 
For the comparisons between the strategies that evaluate the high dose and the low dose 
sequentially, which are A vs. CT1, B vs. CT2, and C vs. CT3, the strategies with the multi-way average 
closed testing are generally as good as or slightly higher in power for both objective and subjective 
assessments to be significant at visit 2, at both visit 2 and 3, or at all three visits, for the high dose, or the 
low dose, or both doses, for all scenarios combined together. The mean numbers of significant evaluations 
for the multi-way average strategies are as large as or slightly larger than its comparators for all scenarios 
combined (Figure A 4.2). 
To see the performance of the strategies that evaluate the high dose and the low dose 
concurrently, the multi-way average closed testing strategies are compared with the corresponding 
strategy A, B, C and D for all scenarios. The powers for the low dose assessments are much higher for 
CT4, with the powers for the high dose evaluations being the same or slightly lower than strategy A at the 
primary visit, and at visit 2 and 3 combined. For all visits combined, the powers for the high dose 
evaluation for CT4 are lower, but they are either not very different than their counterpart, or those powers 
are higher than 0.75 (Figure 4.3). The same thing can be observed for the comparisons between CT5 and 
its counterpart. The powers for the low dose for the strategies CTPA, CTPB and CTPC are consistently 
much higher than their counterparts A, B and C at the primary visit, at visit 2 and 3 combined, and at all 
visits without losing much power for the high dose assessments (Figure 4.4). CTPA also has higher power 
for the low dose or high dose than strategy D at visit 2 and 3 combined, and at all visits (Figure 4.5). 
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Similar patterns are observed for the individual scenarios where treatment effects are reduced at visit 1 or 
reduced for the high dose (Figure A 4.3, A 4.4). 
Powers are compared for the strategies CTPA, CTPB, and CTPC for each of the scenarios at each 
individual visit. CTPC has much higher powers for both assessments to be positive at visit 1 for the high 
dose, the low dose and both doses. It also has good powers at visit 2 and at visit 3 comparing to the other 
two strategies (Figure 4.6). CTPA performs better than the other two strategies in terms of power by a 
small amount at visit 2, but not at the other visits.  
Comparing the strategies with parallel gatekeeping, powers for CTPA, CTPB, and CTPC are 
similar to their counterparts PA, PB, and PC with powers for the multi-way average closed testing 
strategies in the lower power region slightly higher (Figure A 4.5). 
In addition, the mean number of significant evaluations for the multi-way closed testing strategies 
is at least as good as their counterparts, with some scenarios showing substantial increases of significant 
evaluations for the low dose, or for either dose (Figure 4.7, A 4.6). 
Also, the multi-way average closed testing strategy is generally more powerful than the multi-
degree of freedom closed testing strategy for this simulation study (Figure A 4.7). 
All strategies preserve the FWER at the predetermined significance level α. 
4.6 Discussion  
For a confirmatory clinical trial designed to have multiple dose groups, with evaluations taken 
place at multiple visits and with multiple efficacy endpoints at each visit, making primary inference for 
the treatment efficacy needs to be considered carefully. As a common practice, a fixed sequential test 
procedure that combines the Hochberg approach is applied as a solution for this complicated multiplicity 
issue. With this approach, the lower hierarchy of the hypotheses is tested only when all hypotheses in the 
higher hierarchy have significant results. Thus, the “right” order for the specification of the sequential test 
seems very important. However, which dose group is more promising and has low risk for the safety 
assessments, and which visit carries the largest treatment effect are not known a priori.  Therefore, it is 
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challenging to have a powerful yet rigorous strategy that controls multiplicity effectively, while achieving 
the study goal in a pre-specified manner.   
As in the suvorexant studies example, the sponsor has more faith in the high dose, which was 
reflected in the design stage that the high dose had larger sample size and was considered for the primary 
hypotheses. The low dose was examined for secondary (in trial 1) or for exploratory (in trial 2) 
hypotheses.  It turned out that the high dose was associated with safety concerns. Since the evaluation of 
the low dose had lower priority by design, it lacked sufficient power for detecting its signal.  
Several strategies have been developed here to evaluate the high dose and the low dose concurrently.  
Compared to the strategies that evaluate the high dose and the low dose sequentially, those strategies are 
much more powerful for the low dose assessments, without losing much power for the high dose 
evaluation. Since the suvrorexant studies are powered for the high dose, it is of interest to see how those 
strategies perform when the high dose has less strong signal. With the treatment effect reduced more at 
the high dose in the simulation study, the results show a large gain in power for the low dose comparisons 
and a relatively smaller power loss for the high dose only in the strategy CT4 and CT5 for the three visits 
combined, with that power loss being in the high power region (Figure A 4.3). Those results are 
supportive for the strategies that evaluate both doses together instead of in sequence. Compared across 
strategies, the strategies with the closed testing under a parallel gatekeeping framework are generally 
more powerful than the other strategies.  
Also in the suvorexant studies, the efficacy endpoints were collected at each of the three visits. 
Month 1 and month 3 were specified for the primary analyses, while night 1/week 1 was the secondary. 
With the sequential order of testing hypotheses for month 1 first, followed by month 3, and then night 
1/week 1, the power for detecting the positive results decreases for the hypothesis tests that are in the 
lower sequential order. Looking at each of the visits separately, strategy CTPC that evaluates hypotheses 
for all three visits concurrently has much larger powers for the high dose, the low dose, and both doses at 
visit 1 compared to CTPA and CTPB. Strategy CTPB that evaluates two major visits concurrently has 
larger power for the high dose, the low dose, and both doses at visit 3 compared to CTPA. Both CTPB 
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and CTPC have good powers at visit 2 compared to CTPA, which places more emphasis on the visit 2 
assessments (Figure 4.6).     
The parallel gatekeeping strategy is a very powerful approach. It accounts for having a sequential 
order of the test families with multiplicity adjustment taking place within each test family. For a pair of 
parallel sets of sequentially ordered test families each set is tested at 𝛼/2, if one set can be rejected at 
level 𝛼/2, its 𝛼/2 is relocated to the remaining set of the tests so that the tests are conducted at level α. In 
this study, the results show that the strategies with closed testing under a parallel gatekeeping framework 
have better powers compared to the other strategies. The gatekeeping strategy controls FWER in the 
strong sense, so it is very useful for the confirmatory clinical trials. For example, the parallel gatekeeping 
strategy allows the assessments to proceed to the secondary endpoints if at least one hypothesis in the 
parallel test of the primary analysis has been rejected [5].  Also, Dmitrienko et. al developed a tree 
gatekeeping strategy that accounts for the logical relationship among multiple comparisons. It supports 
the decision tree with multiple branches [6]. These procedures can be applied to a wide variety of testing 
problems, for example, ordered primary/secondary endpoints and noninferiority/superiority assessments, 
or ordered primary/secondary endpoints and multiple dose levels. In this study, we discuss the alternative 
strategies that are similar to the scope of the original plan and alternative choices that can be commonly 
used by sponsors. The tree gatekeeping strategy is beyond the scope of this study. 
In summary, a multi-way average closed testing strategy under a parallel gatekeeping framework 
can handle multiple doses, multiple visits and multiple endpoints concurrently. It is powerful and controls 
FWER in the strong sense. 
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Table 4.1 Parameters for the simulation study 
Scenario Mean vector Covariance 
1 Original Estimates 
Observed cov 
2 80% Estimate 
3 50% Estimate for V1, 80% Estimate 
for V2 and 3 
4 80%LD 50% HD 
5 Original Estimates 
Represents 85% sample size 
6 80% Estimate 
7 50% Estimate for V1, 80% Estimate 
for V2 and 3 
8 80%LD 50% HD 
9 Original Estimates 
Represents 70% sample size 
10 80% Estimate 
11 50% Estimate for V1, 80% Estimate 
for V2 and 3 
12 80%LD 50% HD 
13 Original Estimates 
Ratio of the three arms as 1:1:1 
14 80% Estimate 
15 50% Estimate for V1, 80% Estimate 
for V2 and 3 
16 80%LD 50% HD 
17 Original Estimates 
Ratio of the three arms as 1:2:2 
18 80% Estimate 
19 50% Estimate for V1, 80% Estimate 
for V2 and 3 
20 80%LD 50% HD 
21 Null Observed cov 
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Figure 4.1 Diagram of strategies involve closed testing procedure 
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Figure 4.2 Closed testing under parallel gatekeeping 
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Figure 4.3 Power comparisons (A vs. CT4, B vs.CT5) 
 94 
 
9
4
 
 
  
Figure 4.4 Power comparisons (A, B and C vs. CTPA, CTPB and CTPC)  
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Figure 4.5 Power comparisons (D vs. CTPA). 
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Figure 4.6 Power comparisons for CTPA, CTPB and CTPC at each visit. 
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Figure 4.7 Comparisons of mean number of positive evaluations 
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Additional tables and figures 
Table A 4.1a. Observed mean differences between treatment groups 
Outcome Dose Visit 
Observed 
Estimates 
Standard 
Error 
WASO LD 1 -35.54 2.89 
WASO HD 1 -40.68 2.48 
sTST LD 1 14.61 2.72 
sTST HD 1 24.37 2.41 
WASO LD 2 -26.59 3.22 
WASO HD 2 -28.54 2.76 
sTST LD 2 18.54 3.23 
sTST HD 2 23.74 2.85 
WASO LD 3 -24.21 3.27 
WASO HD 3 -26.73 2.81 
sTST LD 3 16.33 3.48 
sTST HD 3 22.29 3.06 
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Table A 4.2b. Covariance structure for the observed estimates. 
  
WASO 
LD at 
V1 
WASO 
HD at 
V1 
sTST 
LD at 
V1 
sTST 
HD at 
V1 
WASO 
LD at 
V2 
WASO 
HD at 
V2 
sTST 
LD at 
V2 
sTST 
HD at 
V2 
WASO 
LD at 
V3 
WASO 
HD at 
V3 
sTST 
LD at 
V3 
sTST 
HD at 
V3 
WASO LD at V1 8.36 3.10 -0.86 -0.34 3.91 1.44 -0.61 -0.24 3.56 1.31 -0.57 -0.22 
WASO HD at V1 3.10 6.16 -0.34 -0.67 1.44 2.86 -0.24 -0.48 1.32 2.61 -0.22 -0.44 
sTST LD at V1 -0.86 -0.34 7.42 2.91 -0.45 -0.18 4.94 1.93 -0.56 -0.22 4.02 1.57 
sTST HD at V1 -0.34 -0.67 2.91 5.79 -0.18 -0.35 1.93 3.84 -0.22 -0.43 1.57 3.13 
WASO LD at V2 3.91 1.44 -0.45 -0.18 10.37 3.83 -0.97 -0.38 4.83 1.78 -0.95 -0.37 
WASO HD at V2 1.44 2.86 -0.18 -0.35 3.83 7.59 -0.38 -0.75 1.78 3.53 -0.37 -0.74 
sTST LD at V2 -0.61 -0.24 4.94 1.93 -0.97 -0.38 10.44 4.09 -0.68 -0.27 7.76 3.04 
sTST HD at V2 -0.24 -0.48 1.93 3.84 -0.38 -0.75 4.09 8.12 -0.27 -0.53 3.04 6.03 
WASO LD at V3 3.56 1.32 -0.56 -0.22 4.83 1.78 -0.68 -0.27 10.70 3.98 -1.06 -0.42 
WASO HD at V3 1.31 2.61 -0.22 -0.43 1.78 3.53 -0.27 -0.53 3.98 7.89 -0.42 -0.82 
sTST LD at V3 -0.57 -0.22 4.02 1.57 -0.95 -0.37 7.76 3.04 -1.06 -0.42 12.14 4.74 
sTST HD at V3 -0.22 -0.44 1.57 3.13 -0.37 -0.74 3.04 6.03 -0.42 -0.82 4.74 9.37 
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Figure A 4.1 Diagram of multiplicity control in suvorexant trials  
Criteria shown is for two-sided α level [1].   
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Figure A 4.2  Power comparisons  
Comparing A, B, C and D vs. CT1, CT2, CT3 and CT4, respectively. 
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Figure A 4.3 Power comparisons for effects reduced at visit 1.  
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Figure A 4.4 Power comparisons for effects reduced for high dose.  
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Figure A 4.5 Power comparisons for strategies using parallel gatekeeping  
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Figure A 4.6 Comparisons of mean number of positive evaluations  
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Figure A 4.7 Multi-way average vs. multi-DF strategy 
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CHAPTER 5 : SUMMARY AND FUTURE RESEARCH 
5.1 Summary 
Previous chapters discuss multiplicity issues under different trial designs that are commonly seen 
in confirmatory clinical trials, and strategies for controlling them. Chapter 1 provides two realistic case 
examples that either have multiple efficacy endpoints evaluated at a visit or a single endpoint evaluated at 
multiple visits. A global test followed by a multi-way average closed testing strategy works well with 
GEE, and can provide odds ratios and multiplicity adjusted p-values for all subsets of hypothesis tests 
with strong control of FWER. 
Chapter 2 addresses multiplicity that originates from evaluating multiple strictly ordinal response 
endpoints in the context of a stratified design, random baseline imbalance, and missing values for an 
osteoarthritis trial. Stratified multivariate Mann-Whitney estimators are applicable to these assessments. 
Randomization based nonparametric analysis of covariance is applied for the random baseline imbalance. 
Multiple imputations and other methods are applied for missing values. For the proposed multiplicity 
strategy with multi-way averages, Mann-Whitney estimators, their corresponding 95% confidence 
intervals, and multiplicity adjusted p-values are produced for the global test and all subsets of hypothesis 
tests.    
Chapter 3 extends the multiplicity strategy with multi-way averages to a more complex situation 
when two or more sources of multiplicity exist simultaneously in one trial. As presented in the realistic 
example, when the primary objective of the confirmatory clinical trial is to make inferences on at least 
one population for a least one endpoint from a design that includes multiple populations and multiple 
endpoints, it is challenging to have a rigorous strategy that controls FWER in the strong sense and is also 
appropriately powerful. For the simulation study using the parameters coming from this real case, the 
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proposed strategy comprehensively meets most of the primary objectives of the trial effectively with 
reasonably high power compared to some more well-known alternative approaches. 
In addition, for a clinical trial that is designed to have efficacy assessed with two or more 
endpoints, for multiple dose groups, and at two or more post-baseline visits, a well accepted multiplicity 
control approach is through fixed sequential testing where the order of the hypothesis tests is defined a 
priori, for example, testing one dose prior to another dose, or testing one visit prior to another visit. When 
it is unclear which dose will perform better, or whether efficacy is better for short-term or long-term 
before the study is conducted, hypothesis tests with the aforementioned strategy may not be very powerful 
or useful. Chapter 4 explores the application for a closed testing procedure with multi-way averages 
combined with a fixed sequential testing approach, or alternatively, the closed testing procedure under a 
parallel gatekeeping framework. A simulation study shows reasonably good power for the proposed 
strategies for managing dose groups equally and evaluating the multiple endpoints at multiple visits 
collectively.       
5.2 Future Research  
Random baseline imbalances may occur in confirmatory clinical trials. Adjusting for baseline can 
correct the random baseline imbalance, better clarify the role of treatments in the comparisons between 
groups, and increase power for the statistical tests through variance reduction.  
The application of conventional parametric ANCOVA is through modeling, for example, the 
linear regression model, the logistic regression model, or the Cox proportional hazards model, and it relies 
on statistical assumptions. In the setting of clinical trials, however, all analyses should be pre-specified in 
order to preserve the validity of the results, with this posing potential dilemmas when the assumptions of 
the parametric ANCOVA are unverifiable. Therefore, the application of nonparametric randomization 
based ANCOVA (NPANCOVA) for randomized clinical trials can be useful. 
For the clinical trials that collect efficacy endpoints longitudinally at multiple visits, patients may 
miss one or more visits. For the longitudinal data analysis that evaluates the change from the baseline 
 112 
 
1
1
2
 
value, subjects with the baseline value and at least one post-baseline measurement are included in the 
analysis model (e.g. Mixed model adjusting baseline as covariate) assuming missing at random (MAR). 
This approach excludes the subjects who do not have post-baseline values from the evaluation (as well as 
those with post-baseline values and no baseline value). Alternatively, we can model baseline and post-
baseline values at each visit as the response variables, and then NPANCOVA will be applied to obtain the 
baseline adjusted mean difference for the responses. With this approach, subjects without post-baseline 
measurements (or without baseline) can be also included in the analysis. 
For a future study, we will discuss the possibility of integrating NPANCOVA with the 
multiplicity strategy that features the multi-way average closed testing procedure, and we will apply this 
approach to real case data analyses. The results from conventional counterparts with parametric 
ANCOVA will be used for comparison.   
 
